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THE GENOTYPE PHENOTYPE CORRELATION OF ICAM1 
K469E GENE POLYMORPHISM AND SEVERITY OF 
RETINOPATHY IN PATIENTS WITH TYPE 2 DIABETES 
MELLITUS  
 
INTRODUCTION 
An emerging  non  communicable  disease with increasing   prevalence  at  an  
alarming  rate  throughout  the  globe is Diabetes Mellitus.  90% of the contribution to 
this emerging epidemic is made by Type   2  Diabetes  Mellitus . India  with  the  
largest  number  of  diabetic  patients,  is  rightly  called  as   “diabetes  capital  of  the  
world”1. 
 
The most severe microvascular complication in Type-2 diabetes patients  resulting in 
impaired visual function is Diabetic retinopathy
2 
which is characterised by the 
presence of microaneurysms, superficial and deep haemorrhages, intra retinal 
microvascular abnormalities, venous beading, , hard exudates, cotton wool spots, 
neovascularistion  of the retina. Late stages of diabetic retinopathy is  complicated by 
pre retinal and intra vitreal haemorrhage leading to blindness. 
 
In 2010 , number of diabetic patients with retinopathy worldwide was 126.6 million  
which is estimated to increase to 191 million by  2030
2
 . India  also face a alarming 
growth  in the percentage of people with retinopathy due to diabetes
4
, thereby an hike 
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in the percentage of diabetic patients who would have vision loss due to this 
condition. In India, Diabetic retinopathy is the sixth leading cause of blindness
4
. The 
age adjusted prevalence of diabetic retinopathy among rural and urban Indian 
population is 18%
5
. 
 
Environmental and genetic factors influence the development of diabetic retinopathy. 
Genetics factors are responsible for  25-50%
6
 of the patients risk for developing 
diabetic retinopathy. The susceptibility to diabetic retinopathy and its variable 
incidence among individuals are largely determined by genetic factors which are not 
dependent upon diabetes duration and blood sugar control . Though polyol pathway, 
activation of protein kinase C,stress due to  oxidative, growth factors upregulation, , 
advanced glycation of end products (AGEs) , adhesion molecules, etc have been 
propose cause the diabetic retinopathy , recently  diabetic retinopathy is described as a 
retinal pathology which is associated with vascular neuroinflammation
7
 which is has 
genetic influence. 
 
Increase in the level of cytokines,  other mediators of inflammation and angiogenesis 
promoting factors  present in  patients with diabetic retinopathy  increase the 
expression of intracellular adhesion molecule 1 (ICAM-1) at endothelial cell surfaces 
,there by  mediating  the processes of adhesion of leukocytes , migration across the 
endothelium and also interaction  with integrins which are  expressed on the surface of 
leucocytes  ultimately leading to stasis of leukocytes within the retina. ICAM-1 in 
vascular endothelium mediates the process of adhesion of leukocytes to retinal 
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vascular endothelium of diabetic patients resulting  in breakdown of blood–retina 
barrier, nonperfusion of capillaries and damage to the endothelial cells and its death 
which predisposes to apoptosis
8
. ICAM-1 also mediator of VEGF in the advanced 
stages of diabetic retinopathy
9
 .  
   
ICAM 1 genetic variants  influence the  expression of ICAM -1 at endothelial cell 
surface .It is associated with microangiopathies including Diabetic retinopathy and 
diseases of immune system like coronary artery disease, Graves disease, inflammatory 
bowel disease, diabetes mellitus Type1 and Behcet’s disease 10-15. The ICAM-1 
K469E (rs5498) polymorphism in  exon 6 causes increase adhesion of LFA-1 and 
Mac-1 on leucocytes to  ICAM-1 on endothelial cells causing leukostasis
16
 .Presence 
of this polymorphism also increases the serum ICAM levels
17
. 
 
Though studies establish a strong correlation between the presence of diabetic 
retinopathy and K469E (rs5498) polymorphism of ICAM-1 gene, the knowledge of 
the  relationship between  this polymorphism and severity of diabetic retinopathy is 
still lacking. This present study aims to investigate the association between K469E 
(rs5498) polymorphism of ICAM-1 gene and severity of diabetic retinopathy in South 
Indian population. 
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Aim  
Primary Aim: 
 To determine the association between K469E ( rs5498) polymorphism of 
ICAM-1 gene and sight threatening diabetic retinopathy. 
 
Secondary aim: 
 To evaluate the relationship between K469E ( rs5498) polymorphism of 
ICAM-1 gene and independent variable like sex, duration of diabetes, insulin 
requirements. 
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REVIEW OF LITERATURE 
Definition of Diabetes Mellitus: 
According to WHO, Group of disorders of metabolism characterized by high blood 
sugar levels h resulting from defective secretion of  insulin, defective insulin action, or 
both
18 comprises diabetes mellitus. 
Classification of Diabetes Mellitus: 
Aetiopathological classification proposed  by World Health Organisation   is as 
follows: 
1.Type 1 diabetes  
Immune mediated 
Idiopathic 
2.Type 2 diabetes 
3.Other specific types 
Genetic defects of  β-cell function 
Genetic defects in insulin action 
Diseases of exocrine pancreas 
Endocrinopathies 
Drug or chemical induced 
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Infections 
Uncommon forms of immune-mediated diabetes 
Other genetic syndromes sometimes associated with diabetes 
4. Gestational diabetes mellitus. 
 
Each of the above mentioned types of Diabetic Mellitus progresses through a stage of 
normoglycemia and hyperglycemia with the management differing in these stages. 
Most of the complications of Diabetes Mellitus develop only during the stage of 
hyperglycemia. The various stages of progression of Diabetes Mellitus can be 
classified as: 
 Normoglycemic stage. 
 Hyperglycemic stage. 
 Impaired glucose regulation - Impaired Glucose Tolerance (IGT) and  
Impaired Fasting Glycaemia (IFG) 
 Established Diabetes Mellitus - Those who don't require insulin 
 Established Diabetes Mellitus - Those who require insulin for control 
 Established Diabetes Mellitus  - Those who require insulin for survival. 
Different types of Diabetes Mellitus and their progression through the different 
glycemic stages is well depicted in the diagram below 
7 
 
 
Figure 1:*These patients experience remissions without requiring continuous treatment known as 
(“honeymoon” remission); **in rare instances, these patients require insulin for survival.18 
Epidemiology of  Diabetes Mellitus: 
According to WHO, the diabetes prevalance worldwide among any age group was 
predicted to rise from 2.8% in the year 2000  to 4.4% in the year 2030 given the 
current situation
18
. A probable increase in the number of patients with diabetes from 
171 million in the year 2000 to 366 million in the year 2030
18
 has been predicted to 
occur. Thus the number of diabetic patients will almost double by 2030.Though  more 
number of women had diabetes than men, prevalence of diabetes was found to be 
slightly higher among men. Middle Eastern Crescent, India , and sub-Saharan Africa 
are the countries where the greatest relative increase was estimated to occur. Of these 
the greatest absolute increase in the number of diabetes patients was estimated in 
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India
18
.5-10% of the diabetic population is compromised by Type 1 diabetes 
mellitus,a90-95% by type 2 diabetes and other types <1%
19
.Hence in this study 
patients with Type 2 diabetes are taken into account since they contribute more to the 
diabetic epidemiology. 
 In India , the estimated total number of type 2 diabetic patients would increase from 
50.8 million in 2010 to 87.0 million by 2030
20
. The prevalence of patients who had 
been already diagnosed with diabetes among  urban areas  was 5.6% and among rural 
areas  it was 2.7% in India
21
. Prevalence of type 2 diabetes mellitus is on rise among 
the rural population as a result of socio-economic transition. The estimated number of 
patients with  type 2 diabetes in India is shown in the following diagram. 
 
Figure 2:Estimated number of patients with type 2 diabetes in India upto year 2030
1
.  
According to the National Urban Diabetes Survey (NUDS), the prevalence of people 
with type 2 diabetes mellitus  among the southern part of  India was higher compared 
32 million
40.9 million
60.9 million
80 miillion
2000 2006 2025 2030
Estimated number of patients with diabetes in India
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to other parts of India. Among the southern parts of India,  number of type 2 diabetic 
patients were highest in Ernakulam with the prevalence rate of 19.5% following this is  
Hyderabad with a prevalence rate of 16.6%  followed by Chennai with the prevalence 
rate of 13.5% which is followed by Bangalore with the prevalence rate of 
12.4%
22,24,25
. 
Figure:3: Type 2 diabetes prevalence in southern India22,23,25,26. 
According to the Chennai Urban Rural Epidemiology Study (CURES) the  type 2 
diabetes prevalence in Chennai in was 15.5 per cent. Type 2  Diabetes Mellitus 
prevalence   in Chennai increased from 1989 to1995 by 39.8 per cent (8.3 to 11.6%); 
by 16.3 per cent (11.6 to 13.5%) between1995 to 2000 and by 6.0 per cent (13.5 
to14.3%) between 2000 to 2004. Thus, the prevalence of  type 2 diabetic patients 
within a span of 14 years  has increased by 72.3 per cent which is significant 
23
.  
Aging global population, ,a rising prevalence of obesity, sedentary lifestyles, 
unhealthy food  habits, urbanization and genetic predisposition are the reasons for the 
predicted  increase in the prevalence of Diabetes Mellitus
24
. 
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Factors contributing to Diabetes Mellitus: 
Obesity : 
Obesity is an important factors driving the global diabetic epidemic. Though 
prevalence of obesity is relatively low in Asia compared to the western population, it 
is growing now due to the development in economic status and urbanisation. The  
Asians have  greater tendency towards fat deposition in the abdomen and decreased 
muscle mass which  termed as “metabolically obese” phenotype predisposes them to 
an increased chance for development insulin resistance
27
 . 
Food habits: 
Foods rich in polyunsaturated  fat  and fibres decreases risk of developing  type 2 
diabetes mellitus, whereas foods with  higher  contents of trans fat and those 
containing higher glycemic load (GL) increases risk of type 2 diabetes. Sugar-
sweetened beverages (SSBs) , intake of fats originating from animals, high caloric 
foods, less f ibre consumption, and regular fast foods intake increases type 2 diabetes 
mellitus risk
28
. 
Physical activity: 
Increased physical activity is associated with decreased risk of diabetes, whereas  
decreased physical activity increase  diabetes mellitus risk2 9 . 
Smoking:  
Cigarette smoking increases the risk of developing type 2 diabetes mellitus and it is 
independent of other risk factors. When compared to non smokers, people who are 
currently smoking had  45%  more chance having type 2 diabetes  mellitus. The risk 
11 
 
of a smoker developing type 2 diabetes is directly related to the number of cigarettes 
he has smoked 
30
. 
The mechanisms by which smoking predisposes people to  type 2 diabetes risk is as 
follows: Cigarette smoking stimulates sympathetic nervous system activity which 
induces plasma cortisol secretion which results accumulation of  visceral adipose 
tissue
31
.Secondly smoking also decreases plasma testoterone  levels in men and also 
has anti-estrogenic effect in women
32
.Nicotine exposure in animal models in pre-natal 
and natal period resulted in dysfunction of beta cell and increased  apoptosis of beta 
cell. 
Alcohol : 
Heavy alcohol intake is associated with increased risk of developing  type 2 diabetes 
,however light-to-moderate intake of alcohol reduces the risk of type 2  diabetes 
mellitus
33
. Simultaneous  use of alcohol and tobacco which is common among Indians 
has an synergistic role on them developing type 2 diabetes
34
 
Dietary habits, inflammation, and type 2 diabetes: 
It has been found in the recent studies that underlying factor in the pathogenesis of 
type 2 diabetes  is  low grade systemic inflammation
35
.Also it has been proved that 
elevated plasma  levels of Intercellular adhesion molecule 1, tumour necrosis factor-
alpha, interleukin-6 and C-reactive protein which are the major inflammatory 
cytokines increases risk of a person getting  type 2 diabetes mellitus.Diet consisting of 
a high percentage of red meat,  refined grains, and sugar sweetened beverages, butvery 
small  percentage of coffee ,yellow vegetables, wine and cruciferous vegetables is 
12 
 
found to increase the  level of above mentioned inflammatory cytokines in the plasma 
which in turn increases the  type 2 diabetes mellitus risk
35
.
   
 
Genetics of Type 2 Diabetes Mellitus  :
 
Though type 2 diabetes mellitus is linked up with upto 40 genetic loci, they are 
responsible only for  a  moderate effect size and do not  clinically predict the type 2 
diabetes mellitus risk beyond the above mentioned traditional risk factors. And also 
there are notable variations in the location of these alleles and  also in their frequency 
among different ethnic groups. Most of the diabetes susceptibility loci are associated 
with impaired function of b eta cell, only a few are related to the  development of 
insulin resistance. This emphasises the fact that b eta cell dysfunction  is the primary 
pathogenesis in diabetes mellitus
29
. 
Gene-environment interaction  predisposing to Type 2 Diabetes Mellitus : 
The  hypothesis of thrifty genotype - 
According to this hypothesis , for efficient functioning of metabolism and also 
for the storage of fat and energy during nutrient scarcity, there occurs a positive 
selection of certain genotypes  called thrifty genotypes.  This over expression of 
the so called thrifty genotypes results in type 2  diabetes mellitus and 
obesity3 6 .This hypothesis proposes that there exists a mismatch between  genes 
of ancestral orgin and modern environment which thereby causes type 2  
Diabetes Mellitus. This hypothesis explains the reason for the increased rate of 
type 2  Diabetes Mellitus among prima Indians. It suggests that in Indians there 
13 
 
occurs an evolutionary selection  of the so called thrifty genes as a result of the 
repeated feast famine cycles predisposing them type 2  Diabetes Mellitus and 
obesity3 7 .However  Southam et al3 8 , found no such thrifty genes responsible for 
either type 2  Diabetes Mellitus or obesity. He also found that there was no over 
expression or increased concentration of any susceptible genetic loci among a 
specific ethnic group. 
The  hypothesis of thrifty phenotype - 
Thrifty phenotype hypothesis states that a  mismatch exists between the intrauterine 
life and adult life is responsible for the development of various chronic disorders ,one 
among which is type 2 Diabetes Mellitus. Nutrition transition is also responsible for 
type 2 Diabetes Mellitus development. It states that as a result of fetal undernutrition  , 
changes in the metabolism and structure (eg: decrease in  the function and mass of 
beta cell and increase in the resistance to insulin) occurs that is required for survival in 
the early life  which  increases the chances of development of type 2 diabetes mellitus. 
This risk increases in the presence of nutritionally rich environment in later life
39
.    
This hypothesis is supported by the fact that “Asian Indian phenotype" with a greater 
circumference of waist and also greater ratio of waist to hip are more prone to get type 
2 diabetes mellitus though the prevalence of obesity defined by body mass 
index(BMI) is lower among them
40
.Also that Indian babies who are smaller at birth 
but are comparitively fatter than the Caucasian counterparts are called as "the thin fat 
Indian babies". The studies confirmed the fact that forerunner of adult diabetogenic 
phenotype
 
 is the persistence of this "thin fat phenotype " into childhood
41
 . 
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Genes causing type 2 Diabetes Mellitus in Indians: 
A variety of genes located on different chromosomes are involved in development of 
type 2 diabetes mellitus. These genes interact with a number of environmental factors 
to give birth to this disorder, which makes genetic analysis further complicated. Single 
gene defect  occurs only in Maturity Onset Diabetes of the Young. Genes which are 
proved to protect against  type 2 diabetes mellitus and resistance of insulin  among 
Caucasians may not have the same protective effect among the Indians. Below is the 
list of few genes which are linked up with type 2 diabetes  in Indians
42
. 
 
Type 2 diabetic genes Association study results 
PPAR γ(Pro12Ala) Pro12Ala polymorphism does not offer any protection 
against(Pro12Ala) diabetes or insulin resistance in South Asian 
population unlike in Caucasian population. 
PGC-1α( Thr394Thr) Obesity and Type 2 diabetes  mellitus are  associated to it. 
PC-1 (K121Q)  Related to type 2 Diabetes Mellitus development. 
IRS-2 (Gly1057Asp) 
 
By interacting with obesity D1057D genotype are 
susceptible to type 2 diabetes mellitus. 
MODY genes  
 
 
South Indians  have different MODY3 mutations than that 
observed in Western populations. 
Ala98Val of HNF1A  mutation  is associated with younger age 
at onset. 
TCF7L2 polymorphism 
(rs12255372) 
Strongly related to Type 2 diabetes mellitus development in 
Indian population. 
Figure :4- Genes associated with type2 diabetes mellitus.
42 
15 
 
 
Diagnostic criteria for Type 2 Diabetes Mellitus:
 
The American Diabetes Association  has recommended the following criteria for 
diagnosis of type 2 diabetes mellitus in 2012
43
:  
HbA1C ≥6.5%a,b         
OR  
Fasting plasma glucose ≥126 mg/ dL (≥7.0 mmol/L)b      
OR  
Two-hour plasma glucose ≥200 mg/dL (≥11.1 mmol/L) during an oral glucose 
tolerance test; 75-g glucose load should be used  
 OR  
A random plasma glucose concentration ≥200 mg/dL (≥11.1 mmol/L) in persons with 
symptoms of hyperglycemia/hyperglycemic crisis  
a
 Test should be performed in a lab using a National Hemoglobin Standardization 
Program-certified method and should be standardized to the Diabetes Control and 
Complications Trial assay.;  
b
  In the absence of unequivocal hyperglycemia, the first 3 criteria listed above should 
be confirmed using repeat testing. 
 
16 
 
 
Pathogenesis of Diabetes Mellitus :
 
 
Resistance to insulin and  dysfunction of beta-cell play role in the production of the 
hyperglycaemia in type 2 diabetics . Even attempts to maintain glucose within the 
normal range does not stop the disease progression. The progressive decline in 
function of beta cell is found to be cause for glucose intolerance .Hence impaired 
insulin secretion due to dysfunction of beta cell  and  resistance to insulin are the 
contributors to the pathogenesis  of Type 2 diabetes mellitus as shown below: 
Figure 5:Pathophysiology of diabetes mellitus. 
Impaired Insulin Secretion: 
Even in the normoglycemic stage , beta cell dysfunction manifests as poor insulin 
response to intravenous glucose and non glucose secretatgogues ,alterations in the 
pulsatile release of insulin and ultra radian oscillatory insulin secretion. As the beta 
cell dysfunction progresses, patient develop Impaired glucose tolerance (IGT) due to 
17 
 
impairment of insulin secretion in the early phase in response to glucose, and a 
decrease in the secretion of additional insulin shortly after meals causing  postprandial 
hyperglycaemia
44
.Progression of impaired glucose tolerance results in increasing 
glucose toxicity and lipotoxicity, thereby resulting in more beta cell dysfunction 
which in turn results in permanent hypoglycaemia
45
 .  
Insulin resistance: 
When there is a disproportion exists between the action exerted by insulin 
concentration in the body and its concentration in blood, it is defined as insulin 
resistance. Insulin resistance is seen prior to disease onset mainly in organs like liver 
and mucles. Insulin receptor belongs to the tyrosine kinase receptors family. Normally 
increased blood glucose levels causes the tyrosine kinase activity of the beta subunit 
of the receptor to be activated. It phosphorylates a substrate protien called Insulin 
Receptor Substrate (IRS-1) which in turn increases the affinity of glucose 
transporter(GLUT-4) molecules to outer membrane of insulin response tissue, 
therefore increasing glucose uptake from blood into these tissues. Various genetic 
factors and environmental factors causes insulin resistance..At cellular level insulin 
resistance is caused by decrease in insulin stimulated tryrosine kinase activity and also 
due to numerical and functional defect in glucose transporters
45
.  
Ocular manifestation due to type 2 Diabetes Mellitus: 
Broad classification Ocular manifestations due to type2 diabetes is as follows: 
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Broad classification Ocular manifestations due to type2 diabetes is as follows: 
 
 
 
 
Non retinal complications of eye : 
 
1.Changes in visual function: a. Reduction of visual acuity: 
This may be due to shifts in refraction, Papillopathy, Cataract, disorders of ocular 
surface, Ischemic optic neuropathy and Other diabetes related ocular changes. 
b. Changes in refraction status
46
: 
Hyperglycaemia channels the sorbitol pathway in the lens. Accumulation of sorbitol 
within the lens draws in more water resulting in increase in lens curvature ,thickness 
and refractive index thereby resulting in myopic shift. However hypoglycaemia 
resulting from treatment causes in flattening of lens and  hence hyperopia.20-40% of 
diabetic patients report vision changes when first diagnosed. 
c. Changes in colour vision: 
Due to diabetic retinopathy ,Colour vision changes like the blue-yellow and red -green 
defects occur which correlate with the diabetes mellitus duration
47
. 
OCULAR MANIFESTATION OF  DIABETES MELLITUS 
DIABETIC RETINAL DISEASE NON RETINAL OCULAR   
COMPLICATIONS 
19 
 
d. Accommodation dysfunction
48
: 
 Transient reduction in accommodation in patients with uncontrolled sugar 
levels which improves on control of sugar levels. 
 Also decrease in accommodation is noted among patients who had undergone 
pan retinal photocoagulation. 
2.Visual field defects:Visual field defects among diabetes may occur secondary to
49
 
 Primary open angle glaucoma. 
 Neovascular glaucoma. 
 Papillopathy 
 Pre retinal or vitreous haemorrhages. 
 Posterior vitreous detachment. 
 Pan retinal laser photocoagulation. 
 Ischemic optic neuropathy 
3.Orbital lesions: 
Diabetic patients  are prone for orbital cellulitis. Orbitorhinomucormycosis caused by 
bread mould (mucor) develop  due to severe acidosis and poor metabolic control  
4. Lids: 
 Ptosis is the most common lid lesion among diabetic patients which is due to 
isolated third nerve palsy. Levator Palpebral Superioris is sensitive to chronic 
hypoxia and hence ptosis. Poor diabetic control results in elevated serum lipids 
causing xanthelasmas of the lids. 
20 
 
 Recurrent hordeolum internum and externum. 
 Chalazion 
5.Abnormal Ocular movements: 
Diabetes mellitus the cause of acute extra ocular muscle palsy in about 25-30% of 
people aged above 45 years
50
. Extra ocular motility disorder in diabetic patients occur 
due to mononeuropathy  involving third,fourth and sixth cranial nerve
48
. However 
other causes of mononeuropathy has to be ruled out in these patients.1 % of diabetic 
patients were found to have ocular motility disorders and of  these 41 % had third 
nerve palsy
51
. 
Third nerve palsy due to diabetes mellitus is characterised by acute painful ptosis with 
exotropia and hypotropia  which become less painful as the duration increases. 
Sparing of the pupil is the most important feature differentiating diabetes mellitus 
related third nerve palsy from other surgical causes.Sixth nerve palsy is characterised 
by the presence of horizontal diplopia with esotropia and abduction deficit.Fourth 
nerve due to diabetes is associated with sudden onset vertical diplopia, vertical 
deviation increasing on looking down or looking away from the affected muscle and 
in head tilt towards the affected muscle side. 
Extraocular motility disorders due to diabetes recovers within 3-6 months. 
Recurrences are common which may affect the same nerve or other nerves
48
. 
Conjunctiva: 
 Microaneurysms in the conjunctiva. 
21 
 
 Lipid imbibition in the conjunctival capillaries. 
 Decreased vascularity of the conjunctiva. 
 Vasoconstriction 
 Vessel distension. 
 Increased tortuosity. 
 Capillary proliferation. 
 More susceptible to bacterial conjunctival infection. 
Tear film
52
: 
Abnormalities of tear film occur commonly with diabetes mellitus.Tear film stability 
is affected in persons with due to diminished tear film breakup time, thereby 
increasing the risk of  ocular surface epithelial defects. Due to the involvement of the 
second division of the trigeminal nerve, corneal sensitivity is decreased  causing 
decreased relex tear secretion.This increases the risk of neurotrophic keratitis. Long 
standing diabetic microvasculopathy may also  affect blood supply to the lacrimal 
gland resulting in impaired lacrimation. 
Cornea
57
 : 
 Prolonged corneal wound healing 
 Recurrent epithelial due to reduction in hemi desmosomes among diabetic 
patients resulting in a weak corneal epithelial adhesion to the underlying 
stroma
53
 
 Corneal ulcers 
 Persistent epithelial defects. 
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 Superficial punctate keratitis. 
 Gerontoxon 
 Limbal vascularisation. 
 Increased incidence of contact lens related microbial keratitis52. 
 Poor clearing of the stromal edema. 
 Pigments at the back of the cornea from iris depigmentation. 
Iris: 
 Depigmentation52 of the iris. 
 Poor mydriasis due to dilator muscle damage. 
 Pin point holes in the iris in retro illumination. 
 Rubeosis iris starting from the pupillary border to involve the angle. 
 Ectropion uvea as  the fibrovascualar proliferation on the anterior surface of the 
iris contracts. 
IOP and Glaucoma: 
Mean IOP in  diabetic population is greater than that in general population. Diabetic 
patients are more prone for developing two major types of glaucoma. 
Primary open angle glaucoma: 
5% of diabetic patients develop primary open angle glaucoma compared to only 2% in 
non diabetics. Primary open angle glaucoma are 1.6 to 1.7 folds common among 
diabetics than the non diabetics
54
.Causes for the increased risk  of primary open angle 
glaucoma among diabetics are as follows
55
: 
23 
 
 Diabetic microangiopathy affects the the anterior optic nerve head perfusion. 
 Impaired autoregulation of posterior ciliary circulation among diabetics further 
impairs the optic nerve perfusion. 
 Presence of concomitant cardiovascular risk factors more commonly among 
diabetics affects the vascularity of the optic nerve head. 
 Diabetic patients are more prone to develop increased IOP and severe field 
loss. 
Neovascular Glaucoma
56
: 
This appears to be the sequelae  of  proliferative diabetic retinopathy, caused by the 
vascular endothelial growth factors diffusing from the posterior segment through the 
pupil and entering  into the anterior segment .The fibrosis accompanying the new 
vessels in the angle may occlude the trabecular meshwork thereby impairing aqueous 
and cause  secondary open angle glaucoma initially which later on progresses to 
secondary open angle glaucoma as the fibrovascular membrane contracts. 
Lens: 
Among diabetic patients , the major cause of defective vision is cataract. Cataracts 
among diabetic patients tend to occur earlier and progress at a faster rate compared to 
non diabetics. Increased Diabetes duration and uncontrolled hyperglycaemia are found 
to increase the risk of development of cataract 
57
.As a result of the above mentioned 
factors, advanced glycation end products ( AGEs) deposit in the lens resulting in the 
formation of cataract among diabetic patients 
57
.Posterior subcapsular cataract and 
cortical cataracts have been reported to be more prevalent among diabetic patients 
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which may be also due to their increase use of statins
58
. Nuclear sclerosis and cortical 
cataract are strongly associated with type 2 diabetes mellitus
57
.Reversible lenticular 
opacities due diabetes mellitus is attributed to uncontrolled blood sugar levels among 
diabetic patients. These bilateral dense bands of white sub capsular spots are called 
snowflake opacities
57
. 
Vitreous: 
 Vitreous syneresis. 
 Asteroid hyalosis 
 Posterior vitreous detachment -Partial PVD increases the risk of proliferative 
diabetic retinopathy and  retinal detachment. 
 Vitreous haemorrhages from new vessels on the retinal surface projecting into 
the vitreous. 
Optic disc: 
a. Diabetic papillopathy: 
Diabetic papillopathy diagnosed by the presence of hyperemic disc swelling in one or 
both the eyes .Defects in the visual field and  afferent pupillary defect  may or may not 
be associated with this.
59
. It should be differentiated from other causes of papilledema 
and optic disc swelling. Telangiectasia at the disc may be mistaken for proliferative 
diabetic retinopathy. 
It is a risk factor for diabetic retinopathy proliferation
60
. It is now proposed as a mild 
and reversible form of Anterior Ischemic Optic Neuropathy
61
.It is not associated  with 
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degree of diabetic retinopathy or glycemic control.Visual acuity is moderately 
decreased and prognosis is very good. Most people regain vision by one year .Control 
of blood sugar ,systemic hypertension ,renal function improvement may play role in 
the resolution of vision . 
Ischemic optic neuropathy: 
Patients with diabetes mellitus are more likely to develop anterior ischemic optic 
neuropathy after the age of 67 years
62
. It is caused by microangiopathy of the optic 
nerve head.It is characterised by swelling, haemorrhage, sudden vision loss, afferent 
pupillary defect and visual field defects. It results in optic atrophy and decreased 
visual acuity. Diabetic papillopathy and anterior ischemic optic neuropathy can be 
differentiated by its younger age of onset of the former.25% of anterior ischemic optic 
neuropathy have diabetes
57
. 
Retina: 
 Diabetic retinopathy 
 Lipemia retinalis. 
Ocular  manifestations other than Diabetic Retinopathy depending upon its 
relation to diabetes mellitus can be broadly classified as follows
57
: 
Ocular manifestations due to diabetes: 
 Cataract. 
 Anterior ischemic optic neuropathy 
 Diabetic papillopathy 
26 
 
 Ocular movement disorders. 
Ocular manifestations with diabetes as a risk factor: 
 Primary open angle glaucoma. 
 Neovascular glaucoma. 
 Ocular ischemic syndrome. 
 
Ocular manifestations with diabetes as a possible risk factor: 
 Central/Branched Retinal vein occlusion 
 Central/ Branched Retinal artery occlusion 
 Retinal arteriolar occlusion. 
 Corneal diseases. 
 
Ocular conditions mimicking diabetic eye disease: 
 Age related macular degeneration. 
 Hypertensive retinopathy. 
 Radiation retinopathy. 
 Other causes of retinopathy like HIV/AIDS, Giant cell arteritis, , Bechet’s 
disease, SLE, Wegener’s granulomatosis, sickle cell disease, retinal 
telangiectasia etc.and sarcoidosis  
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OCULAR MANIFESTATION OF TYPE 2 DIABETES MELLITUS: 
 
                           
                                                                                     
 
 
 
 
Fig6: Hordeolum Externum Fig 7:Chalazion 
Fig 11:Rubeosis Iris. 
Fig:8 Corneal epithelial defects 
 
 Fig:14 Corneal epithelial defects  
 
Fig:9  Snowflake cataract 
Fig :10 Asteroid Hyalosis. 
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Diabetic Retinopathy 
Epidemiology of diabetic retinopathy: 
The alarming rise in diabetic prevalence has lead to the emergence of diabetic 
retinopathy as the leading cause of blindness among the working age population. 
Among the various types of diabetes mellitus, most common form is type 2 diabetes 
mellitus .WHO estimates that 300 million will have type 2 diabetes mellitus by 
2025.During the last two decades there has been increasing reports of diabetic 
retinopathy due to type 2 diabetes mellitus especially from Asia. 
According to a study done in 2012, the number of people in the world with diabetic 
retinopathy is 93 million, of these 17 million have proliferative type of retinopathy 
due to diabetes ;Clinically significant macular edema was present in 21 million due to 
diabetes and 28 million had sight threatening retinopathy due to diabetes.
63 
Prevalance of Retinopathy due to diabetes among the western population: 
63
In the united kingdom the diabetic retinopathy prevalence  is 30%,among these 3% 
had proliferative type of  retinopathy and 6% had  clinically significant macular 
edema due to diabetes..
 
In Europe, diabetic retinopathy prevalence  is 32% in France,38.7% in Denmark,34% 
in Italy,34.2%in Russia and only 45% in Finland. The proliferative diabetic 
retinopathy prevalence among various European are as follows:3% in France,0.9% in 
Denmark,5% in Italy,2.75 in Russia. The prevalence of macular edema is highest in 
Denmark (12.8%) followed by France(5%)These differences may not be appropriate 
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due to the different methodologies employed. Retinal photographic studies among the 
whites reveal the diabetic retinopathy prevalence to be 40% and that of sight 
threatening  retinopathy due to diabetes  to be 6-8%.  
In United  states,  the non-Hispanic whites had  similar diabetic retinopathy 
prevalence as among white patients in Europe(40%). The incidence of new diabetic 
retinopathy among type 2 diabetic patients in United States is between 5% and10% 
per year. The diabetic retinopathy risk and  likelihood of developing clinically 
significant macular edema were more common among Hispanics and African-
Americans. The Hispanics were 3 times more prone to develop clinically significant 
macular edema whereas the Hispanic whites are 2.5 times more risk of developing 
CSME. 
Prevalence of retinopathy due to Type 2 Diabetes mellitus in Asia
63
: 
In Asia maximum number of  diabetic retinopathy patients  s are in India and China . 
The diabetic retinopathy prevalence  among newly diagnosed  type 2 diabetics  in  
Pakistan (15%)  ,Sri Lanka (15%),and Nepal (19.3%)is high compared to India. The 
diabetic retinopathy prevalence  among  the newly diagnosed Chinese urban 
population ranges from 21% to 21.9%.which is less common  than  those seen in rural 
China (33.5%). This is in contrast to clinical scenario in India where the diabetic 
retinopathy is more common in the urban population compared to the rural population. 
According  to the Beijing Eye Study diabetic retinopathy was responsible for only 
7.7% of blindness. This is mainly due to increased awareness, regular followup and 
prompt treatment. 
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Diabetic retinopathy prevalence among Type 2 Diabetics  in Australia
63
: 
5-year cumulative incidence of Diabetic Retinopathy (22.2%) was lower than the 
incidence (32.7% ) of diabetic retinopathy  after 4 years among non-insulin treated  
predominantly white type 2 diabetic population. This may be due to good awareness 
about the probelm among the public and better blood sugar control in Australia. 
According to the Melbourne Visual Impairment Project , incidence of Diabetic 
Retinopathy after 5 year period was 11%, with most patients with sight-threatening 
disease receiving treatment. Among various ethnic groups in Australia, annual 
incidence of sight threatening diabetic retinopathy  is  highest among Australian 
Aborigines (1.2%) and also  the incidences of clinically significant macular edema  is 
highest among this ethnic group. 
Diabetic Retinopathy due to Type 2 Diabetes  in India: 
Among Indians the diabetic retinopathy prevalence among with type 2 diabetic 
patients is lower when compared to the whites. However India with the highest 
number of estimated diabetic population,has more number of patients affected by 
diabetic retinopathy
63
. Diabetic retinopathy has become the sixth cause of blindness in 
India. Studies based on retinal photography revealed a lower Diabetic Retinopathy 
prevalence  among  type 2 diabetics (18%)  compared to the western population. And 
also in India the Diabetic Retinopathy prevalence among newly diagnosed type 2 
daibetes is low (5-7%) compared to neighbouring areas
63
. Studies show that 
prevalence of diabetic retinopathy as more among urban (17.8-18%)population 
compared to the rural population(5-10%)
64,65,66
.In  India the rate of development of 
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clinically significant macular edema among patients with type 2 diabetes mellitus is 
high. According to the population based study done by Sankara Nethralaya,one third 
of the patients with type 2 diabetes mellitus had any degree of macular edema , 
however only 6.27% developed clinically significant macular edema 
(CSME)
65
.Similar results were  found in the Chennai Urban Rural Epidemiology 
Study (CURES) study, where  Macular Edema prevalence was lower among newly 
diagnosed diabetics(1.1%) compared to the among known type 2 diabetics (6.3%)
 64
.  
Diabetic retinopathy in Tamil Nadu:  
According to a population based study done by evaluating fundus photographs done in 
Chennai by Shankar Nethralaya, the prevalance of diabetic retinopathy among the 
general population was 3.5% while that in type 2 diabetic patients was 18%
65
. 
According to the Chennai Urban Epidemiology Study (CURES) ,occurrence of  
diabetic retinopathy among general population was 17.6% with a prevalence of 20.8% 
among the known diabetics and 5.1% among the newly diagnosed diabetics
64
. Male 
gender, long duration of diabetes, known diabetics, proteinuria are the risk factors 
increasing the development of diabetic retinopathy in urban population in Tamil Nadu. 
An increase of 2% of glycosylated haemoglobin was associated with 1.7 times 
increase risk of diabetic retinopathy. As the duration of  diabetes increases by 5 years 
the risk of developing diabetic retinopathy increased by 1.89 folds
64,65
. 
According to a population based cross sectional study done in rural Tamil Nadu by 
Shankar Nethralaya, the diabetic retinopathy prevalence type 2 diabetic patients is 
10.3%. The prevalence of  diabetic retinopathy was more among known diabetics 
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(13.1%) than in those who were newly diagnosed (2.8%).Prevalence of sight 
threatening diabetic retinopathy was 3.8% , with a prevalence of 5% among known 
diabetics and 0.6% among newly diagnosed diabetics
66
. Male gender, use of insulin, 
longer duration of diabetes mellitus, systemic hypertension, poor control of blood 
sugar  are the risk factors for the diabetic retinopathy development  among the rural 
population of Tamil Nadu
66
.While comparing the data on the diabetic retinopathy 
prevalence between the rural and urban populations of  Tamil Nadu ,higher prevalence 
of  diabetic retinopathy in the newly diagnosed was found in urban population(6% ) 
than the rural population(2.8%). However, the newly diagnosed diabetics had low 
prevalence of sight threatening diabetic retinopathy both in urban(0.4%) and rural 
population(0.6%)
65,66
.Though when compared with other ethnic groups, the diabetic 
retinopathy prevalence is lower in  South Indians, due to the huge diabetic population 
in Tamil Nadu, diabetic retinopathy  is a major health probelm in Tamil Nadu
66
. 
Diabetic Retinopathy risk factors: 
Duration of diabetes: 
               After 3-4 yrs of type 2 diabetes mellitus, 30% had developed retinopathy  
and 2% had developed proliferative retinopathy. After 20 years, 60% had developed 
retinopathy and 5% had developed proliferative diabetic retinopathy
67
. 
Hyperglycaemia: 
According to The Diabetic Control and Complications Trial (DCCT), tight glycaemic 
control resulted in an initial worsening of diabetic retinopathy . However after three 
years of  strict glycaemic control ,this pattern reversed as a result of which  
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progression of diabetic retinopathy decreased by 54%
68
.In this study it was also 
proved that incidence of diabetic retinopathy decreased by 76% when blood sugar 
levels were maintained within normal limits
68
. Similar results were are seen in the 
United Kingdom Prospective Diabetes Study Group(UKPDS) , where a 25% decrease 
in the occurrence of diabetic retinopathy was seen in patients on intensive blood 
glucose control
69
. 
Glycosylated Haemoglobin levels: 
In the WESDR study,the  four and ten years incidence, course of progression of 
,progression to proliferative type of diabetic retinopathy and development of macular 
edema were predicted by baseline glycosylated haemoglobin levels. Moreover, a 
decrease in the glycosylated haemoglobin levels over a period of 4 years lead to 
slowing down  the progressive course of diabetic retinopathy and decrease in the 
occurrence of proliferative type of retinopathy
70
. 
Endogenous/Exogenous Insulin: 
Though low levels of C-peptide in the blood  was associated with severe retinopathy 
due to juvenile onset diabetes, severity of the retinopathy due to type 2 diabetes 
mellitus was not associated with blood C -peptide levels . And also dosage and type of 
exogenous insulin did not influence the diabetic retinopathy severity
 71
. 
Age: There was a marked rise in the diabetic retinopathy frequency due to type 2 
diabetes in those younger than 50 years. However after 50 years, there was little 
relationship between the severity and age of the patient. According to Framingham 
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Eye Study, the frequencies of diabetic retinopathy due to type 2 diabetes increases 
with age which is shown in the table below. 
  
 
Age at  time of diagnosis: 
Though no relationship was present between the age of diagnosis of type 2 diabetes 
mellitus and the diabetic retinopathy incidence or progression  in Wisconsin 
Epidemiologic Study of Diabetic Retinopathy (WESDR), Minnesota eye study found 
that younger the age of onset of type 2 diabetes more the chance of diabetic 
retinopathy development 
73
. 
 
Pregnancy and puberty: 
During puberty increase in the sex hormones ,growth hormones, insulin resistance and 
systolic pressure may favour development of diabetic retinopathy especially among 
non insulin dependent diabetics. Hence the duration of diabetes in the prepubertal age 
is an important risk factor .Pregnant patients with type 1 diabetes have two times 
increased risk of  developing proliferative diabetic retinopathy. Hence frequent retinal 
18% 16.80%
25.90%
52-65 yrs 65-74yrs >75 yrs
Diabetic retinopathy Frequency  among different 
ages
Figure:12: Frequency of diabetic retinopathy among different age groups
72
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examinations and aggressive treatment instituted to prevent loss of vision in this high 
risk situation. 
Race: 
Though the diabetic retinopathy prevalence  among type 2 diabetics  is low , the 
increasing number of diabetic patients in India has made diabetic retinopathy one of 
the leading cause of blindness. 
Hypertension: 
Increase in the presence and rapid progressive course of diabetic retinopathy and 
macular edema is seen among hypertensives
67
. Higher diastolic pressure is associated 
with higher incidence of macular edema in diabetic patients. Progression of 
retinopathy slows down by34%  and visual acuity improves by 47% with strict control 
of hypertension
69
. According to Barbados Eye Study, When the systolic pressure 
increases by 10 mm Hg,the risk of developing diabetic retinopathy increased by 30% 
among African- Americans and also that antihypertensive treatment halved the risk
79
. 
Serum lipids: 
Various studies confirm the association between the serum lipids and the presence of 
hard exudates in the retina. Increased serum lipids is associated with more chance of 
the patient having hard exudates in the retina. However this is more common among 
the insulin using population
67
. 
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Renal disease: 
Presence of any kidney disease may aggravate the progression of diabetic retinopathy. 
Co-existing hypertension, increased duration of diabetes may also confound the 
effects of renal disease on diabetic retinopathy. Presence of proteinuria among type 1 
diabetic patients increases the chance of developing proliferative type of diabetic 
retinopathy. The prevalence of diabetic retinopathy increased from 7% at the onset of 
microalbuminuria to 29% after 4 years of onset
74
. Therefore regular eye checkups are 
advised in younger onset diabetic patients with gross proteinuria 
74
. Patients with 
microalbuminuria showed greater prevalence with increased severity of diabetic 
retinopathy  when compared to those with to microalbuminuria and 
normoalbuminuria.
75
 
Anaemia: 
Low haematocrit increases the risk of developing high risk proliferative diabetic 
retinopathy
76
. Patients with haemoglobin less than 12 g/dl has two fold increased 
chance of having diabetic retinopathy compared to those with higher haemoglobin
77
. 
Obesity: 
Increased body mass index increases the chance of developing both diabetes and 
diabetic retinopathy. However presence of other factors increasing the chance of one 
getting diabetic retinopathy such as insulin resistance and uncontrolled blood sugar 
levels which accompany diabetic patients with obesity may predispose a patient with 
increased body mass index to develop diabetic retinopathy. 
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Exercise: 
Women with increased physical activity are less prone for the development of 
proliferative  type of retinopathy due to diabetes 
67
. No such effect is seen in men
78
. 
However there has been concern that increased physical activity ahs detrimental effect 
on retinopathy and vision in advanced retinal disease due to elevated systolic pressure 
subsequently leading to vitreous haemorrhage and also further compromise in oxygen 
supply. However this has not been proved. 
Nutritional factors: 
There is no enough studies to recommend high dose antioxidant supplementation to 
prevent the incidence and progressive course of diabetic retinopathy among patients 
with Type 2 diabetes. According to San Luis Valley Diabetes Study, there was no 
protective effect offered by the antioxidants against the development of retinopathy 
among type 2 diabetic patients
80
. 
Smoking: 
Though one may except high incidence of diabetic retinopathy among smokers due to 
ischemia and hypoxia, there is no consistent association between the two
81
. However 
smoking is strongly associated with cardiovascular disease and nephropathy among 
diabetics which may increase the incidence and progression of diabetic retinopathy . 
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Alcohol intake: 
According to the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), 
young diabetic patients who consume alcohol are less prone to develop proliferative 
retinopathy. However after 6 years ,this association does not exist 
82
. 
Socioeconomic status: 
According to the Wisconsin Epidemiologic Study of Diabetic Retinopathy 
(WESDR),Women who were well educated had relatively lesser occurrence of 
diabetic retinopathy
 67
. However poor socioeconomic status did not result in 
worsening of retinopathy. According to a study done in urban India, newly diagnosed 
old patients with diabetes in the upper or middle socioeconomic class had 86% higher 
risk of developing retinopathy than those belonging to the lower or extreme lower 
socioeconomic class
83
. However this association was statistically significant. Hence 
one can conclude that socioeconomic factors doesn't influence the course of diabetic 
retinopathy once the blood sugars under control. 
Genetics of Diabetic Retinopathy: 
The role of genetics in the development of diabetic retinopathy is evident from the fact 
that only 50% of patients with  NPDR progress to develop PDR and also many 
diabetic patients never develop diabetic retinopathy. There are various candidate 
genes which are suspected to influence the occurrence of diabetic retinopathy by 
modifying the polyol pathway or by playing a role in  the formation of advanced 
glycation end products (AGE) or by predisposing to  hypoxia induced angiogenesis or 
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by predisposing the inflammatory changes . Few are the candidate genes are discussed 
below. 
Aldose Reductase gene: 
The aldose reductase pathway is the major factor influencing the occurrence of 
diabetic microvascular complications. The rate limiting enzyme of this pathway is 
Aldose reductase(ALR2).Normally only a very  small fraction of glucose is 
metabolised through sorbital pathway. But during hyperglycemia as seen in diabetes, 
relatively large portion of glucose gets metabolise by this pathway resulting in the 
accumulation of sorbital intracellularly and resulting in osmotic stress which leads to a 
series of cellular changes cumulating in diabetic retinopathy 
ALR gene (AKR1B1) is located on chromosome 7q35 which codes for aldose 
reductase(ALR2) is the most significantly associated with DR .Three single nucleotide 
polymorphisms are linked up with the diabetic  retinopathy development and they are 
SNP rs9640883, the (CA)n microsatellite polymorphism located at 5’ of the ALR 
gene, promoter SNP rs759853 
84
. 
Of the three alleles of (CA)n microsatellite ,z-2 allele is significantly associated with 
non-proliferative and proliferative Diabetic Retinopathy  in both type 1 and type 2 
diabetes. However the z+2 allele  of the (CA)n microsatellite and allele  T of single 
nucleotide polymorphism rs759853 has protective effect against  Diabetic 
Retinopathy. The single nucleotide polymorphism rs9640883 predisposes to earlier 
onset of diabetes and so increased diabetic duration rather than a direct effect on 
increasing the risk of Diabetic Retinopathy.
84  
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Human Leukocyte Antigens: 
A strong association is present between human leukocyte antigen (HLA) and the  
occurrence  and severity of diabetic retinopathy. According to a case control study 
done by Rand et al, HLA-DR 4/0 ,HLA-DR 3/0 and HLA-DR X/X  is linked with 
proliferative diabetic retinopathy due to type 2 diabetes. However HLA DR 3/4, HLA 
DR 3/X and HLA DR 4/X  is not associated proliferative type of diabetic 
retinopathy
85
. 
Vascular Endothelial Growth Factor (VEGF) Gene
86
: 
VEGF is an endogenous cell specific mitogen which results in development of 
retinopathy among diabetics. Due to hypoxia and hyperglycaemia which occurs in 
diabetic retinopathy, VEGF expression is stimulated which results in increased VEGF 
in blood and also increased expression of VEGF receptors in diabetic retina 
cumulating in formation of new vessels. The VEGF gene is present  in chromosome 6 
(6p21.3) and alternate splicing of its exon results in two families of VEGF 
proteins.SNPs in the promotor region  of the VEGF gene has been known to influence 
diabetic retinopathy development. The Single nucleotide polymorphism of the VEGF 
gene predisposing to one population to diabetic retinopathy may not predispose 
another population of different ethnicity to diabetic retinopathy risk. 
In the Japanese population , the CC allele at the C(-634)G region in the VEGF gene 
predisposes them to diabetic retinopathy . The  C allele of this single nucleotide 
polymorphism is associated with higher serum levels of VEGF, higher expression of 
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VEGF-A receptors in the human retina and also increased development of macular 
edema
86
.  
This C allele single nucleotide polymorphism association with diabetic retinopathy 
has not been confirmed in the Caucasian population. On the other hand, GG genotype 
of this single nucleotide polymorphism results in diabetic retinopathy among 
Caucasians. Further CA genotype of promoter -2578 polymorphism of the VEGF 
gene and SRp552994 polymorphism of one of the splicing factors which control 
alternative splicing thereby disrupting the balance in  the proportion of pro and anti 
angiogenic VEGF isoforms influence the occurrence of diabetic retinopathy  in 
Caucasian population. Among Indians ,the CG genotype at the C(-634)G region 
increases the occurence diabetic retinopathy
87
. 
Receptor for Advanced Glycation End Products Gene
86
: 
Non-enzymatic glycation of protein and lipids resulting  from uncontrolled blood 
sugar level leads to the formation of Advanced Glycation End  products (AGES) 
which act on specific receptors for advanced glycation end products (RAGE) causing 
direct tissue damage by initiating pro inflammatory cascade. The gene coding for 
RAGE belonging to the immunoglobin super family located on chromosome 6p21.3 
increase the risk of developing diabetic retinopathy. 
Though -374T/A polymorphism which up regulates  RAGE transcription by binding 
to a transcription binding site,Gly82Ser polymorphism and -429T/C polymorphism 
are associated with diabetic retinopathy in few independent studies, meta-analysis of  
these three polymorphism revealed no association with diabetic retinopathy. However, 
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the 1704T allele  among  East Asian populations and 2245A allele  among  Malaysian 
population was associated with an increased risk of DR
88
 . 
Endothelial Nitric Oxide Synthetase gene(eNOS): 
Formation of nitric oxide from L-arginine is catalysed by endothelial nitric oxide 
synthetase and this enzyme is coded by a gene located in the chromosome 7q35-26 
and its polymorphism is associated with increased risk of developing diabetic 
retinopathy .From various meta analysis it has been concluded that 
 Association of a/b polymorphism of intron 4 eNOS gene ,C allele of T-786C 
polymorphism and G894T polymorphism  with diabetic retinopathy could not 
be confirmed
89
. 
 4a allele of 4b/a polymorphism and C allele of T-786 polymorphism decreases 
the risk of diabetic retinopathy
89
. 
Angiotensin-I Converting Enzyme (ACE): 
Increased expression of Angiotensin -I Converting Enzyme has adverse effects on 
retinal blood flow and vascular structure resulting in neovascularisation. The gene for 
this enzyme is located in chromosome 17q23 
 Insertion/Deletion polymorphism has been associated with proliferative 
diabetic retinopathy but not with non proliferative diabetic retinopathy among 
the caucasian population. 
 ACE 2350 G/A polymorphism is also associated with diabetic retinopathy 
among Chinese population
90
. 
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Erythropoietin gene(EPO): 
Erythropoietin is an angiogenic factor expressed  in retina and kidney with its gene 
located at chromosome 7q21. Initially it acts as a neuroprotective element  in the 
retina and protects against diabetic retinopathy but in  advanced stages it acts 
synergistically with VEGF and worsens diabetic retinopathy., T allele of promoter 
SNP rs1617640 predisposes European-American type 1 diabetic population  
proliferative diabetic retinopathy in the presence of diabetic nephropathy but not with 
proliferative diabetic retinopathy in the absence of nephropathy
86
. 
Peroxisome Proliferator Activated Receptor -γ2 (PPARγ2) gene:  
A1a allele of the Pro12Ala polymorphism has protective effect against  the 
development retinopathy  due to type 2  diabetes among the Caucasians. However it 
offers no protective effect among the Asian population against the development of 
retinopathy due to type 2 diabetes mellitus
86
. 
Interacellular Adhesion Molecule (ICAM) gene polymorphism and 
Diabetic Retinopathy 
ICAM-1 also known as CD54 belongd to immunoglobulin super family and is 
expressed by leukocytes and endothelial cells. ICAM 1 is a transmembrane 
glycoprotein with 5 extracellular domains with amino terminus, a single 
transmembrane domain and a carboxy cytoplasmic domain. The  secondary structure 
of this protein is beta sheet
91
. 
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Regulation of ICAM-1
92
: 
ICAM -1 expression is regulated in a cell specific manner by the following pathways
92
   
 The NFκB pathway. 
 JAK/STAT and IFN-  
 AP-1 and MAP Kinase 
 Protein kinase C pathway. 
These pathways regulate ICAM expression at the level of transcription. The NFκB 
pathway is the most common inducer of the ICAM -1 in cells  which is prompted by 
proinflammatory cytokines such as TNF-  and IL-1 activate NIK via different 
receptors. Interferon -γ has a signalling effect on the transcription of ICAM-1 through 
JAK/STAT pathway
93
 .Other growth factors and cytokines activate the AP-1 promoter 
of the ICAM-1 through a complex pathway. However this pathway offers a more 
controlled expression of Icam-1 than the TNF-  and IL-1 promoted pathway when 
induces by uncontrolled factors like stress or oxidants. Protein kinase  C 
(PKC) indirectly activates the expression of ICAM-1 and it is required for the 
expression of ICAM-1 by mediators like TNF-α, IL-β,INF-γ and other stress factors. 
The primary receptor for ICAM-1 are intergrins though they do not contain  a RGD 
(Arg-Gly-Asp) motif to promote intergrin binding.By binding with these intergrins 
ICAM-1 mediate cell-cell interactions and allow for signal transduction
91
.ICAM-1  
specifically bind to two intergrins of β2 subunit namely LFA-1 and Mac-1 on the 
leukocyte surface and thereby mediate  T-cell function  and activation and leukocyte-
endothelial cell interaction
94
. 
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Function of ICAM-1: 
ICAM-1 and LFA-1 interaction is the primary step in the antigen recognition by the 
CD8 cells which allows time for the T cell receptor to align with the MHC-II and 
peptide complex. A successful T cell receptor interaction will increase the adhesive 
forces and commence the effector function. ICAM-1 along with the MHC-I in the 
antigen presenting cells play a similar role in CD4 cells activation
91
. 
Selectins like P, E and L initially instigate upon the leukocyte a rolling behaviour over 
the endothelial cells.ICAM-1 ,whose expression is upregulated by inflammation 
interacts with the leukocyte LFA-1 and MAC-1 and stablises the interaction. The 
arrested leukocytes begins diapedesis with teh help of protein called PECAM which is 
present in both endothelial cells and intercellular junctions of endothelial cells. 
Though ICAM-1 intergrin interaction is not specific, ICAM-1is specifically 
upregulated by certain cytokines, thus controlling the nature of inflammatory 
response
95
.ICAM-1is shed by the cells and seen in the plasma as sICAM which is 
elevated in a number of pathological conditions.Other ligands for ICAM-1 include 
Figure:14-JAK/STAT regulatory 
pathway of ICAM-1
92
. 
Figure:13- NFkB or AP-1 MAPK regulatory 
pathways of ICAM-1
93
. 
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plasmodium falciparum affected RBCs,CD43 ,soluble molecular fibrinogen, matrix 
factor hyaluron.ICAM-1 acts as a receptor for  rhino viruses
91
.  
Figure15:ICAM mediated stable adhesion and diapedesis of leukocytes. 
ICAM-1 Gene: 
ICAM-1 gene is a protein coding gene located in the chromosome 19p13.2 with the 
size of 15781 base pairs and has a plus strand orientation. It starts from 10,381,511 
base pairs from pter and ends at 10,397,291 base pairs from pter 
 
Figure 16: ICAM-1 gene location at chromosome 19p13.2 
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Single nucleotide ICAM gene polymorphism : 
Single Nucleotide Polymorphism(SNP) is a variation in a genetic  sequence of DNA 
that occurs in the genome when there is alteration of a single nucleotide . It has been 
proposed that these are  point mutation which are evolutionarily successful to recur in 
a considerable portion of population of a species. For example nucleotide cytosine 
may be replaced by nucleotide thymine in a stretch of DNA. Always SNP has two 
alleles and their frequency vary among different ethnic groups. Normally SNP occur 
once in every 300 nucleotides in an individual DNA and they are found between the 
genes. Mostly they occur in a non -coding region. When they occur within the coding 
region ,they alter the gene function and lead to a particular disease. Most SNPs do not 
have a phenotypic effect. But SNPs involving the coding region may predict the 
individual susceptibility to certain drugs or environmental factors such as toxins  and 
also susceptibility to a particular disease
96
.  
Recently it has been found out that K469E and G241R are the two polymorphisms of 
the ICAM-1 gene causing several microangiopathies like diabetic retinopathy, 
vascular dementia ,stroke, peripheral arterial occlusive disease and also immune 
mediated diseases like Type 1 diabetes, Graves disease, Behcets disease, Coronary 
artery disease and Inflammatory Bowel Disease. Howver they are related only to 
diabetic retinopathy and not diabetes
99
. 
The K469E ICAM polymorphism change gene function by two mechanisms: 
 As a result of the K469E polymorphism, 5th  immunoglobulin like domain of 
ICAM-1 which has lysine changes to glutamine thereby influencing 
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dimerisation and hence altering structure thereby increasing the affinity to the 
leukocytes
97
. 
 The K469E polymorphism produces alternatively spliced short isoforms 
(ICAM-1s) which has only extracellular domain  influences signal transduction 
of ICAM and intercellular contact. It also increases the apoptosis resulting in 
endothelial injury. The exhausted regenerative capacity of the endothelium 
along with diabetes induced defective endothelial repairing capacity results in 
vascular damage and macrophages influx which further amplifies the ischemic 
nature of diabetic retinopathy
97
.All these cumulates in exacerbation of diabetic 
retinopathy as shown in the picture below.  
 
 
 
 
 
Figure:17-Role of ICAM in diabetic retinopathy. 
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K469E ICAM gene polymorphism and diabetic retinopathy association 
studies: 
97
Vinitha et al  studied ICAM-1 K469E polymorphism among  Indian Type 2 Diabetes 
patients with retinopathy and without retinopathy . They concluded that allele A of 
rs5498 in ICAM-1 predisposes the patient to develop retinopathy due to type 2 
diabetes mellitus by decreasing the folding rate of the protein and thereby its structure 
and function. 
 
98
Petrovic and his colleagues studied the association of ICAM-1 K469E 
polymorphism and proliferative type of retinopathy due to diabetes in Caucasian 
population and concluded that EE genotype of the K469E ICAM-1 polymorphism 
predisposes the Caucasians to develop diabetic retinopathy. 
 
99
Liu L found that K469E ICAM-1 gene polymorphism among Chinese diabetic 
patients is related to type 2 diabetic retinopathy.  
100
Balasubbu S evaluated  the association of nine candidate gene polymorphisms of 
type 2 diabetic retinopathy among Indian patients one among which is ICAM-1 gene. 
However only rs2070600 polymorphism of  RAGE gene was associated with type 2 
diabetic retinopathy among Indian patients. In this study ,ICAM-1 gene was not found 
to be influencing the development of diabetic retinopathy. 
101
Kamiuchi K et al evaluated the role of ICAM-1 and PECAM in predisposing to 
Type 2 diabetic retinopathy. In their study, only patients with  ICAM-1 469KK 
genotype was predisposed with type2 diabetic retinopathy. 
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Pathogenesis: 
Biochemical Mechanisms related to diabetic retinopathy pathogenesis: 
1.Aldose reductase theory
84
: 
             Excess glucose in blood in Type 2 diabetes mellitus 
             Sorbital /Aldose reductase pathway intracellularly 
             Excess sorbital intracellularly which is osmotically active. 
             Accumulation of water intracellularly. 
1. Pericyte loss  
2. Adverse effects on retinal photoreceptor function and  
retinal blood flow 
3. Vasodilation. 
 
2. Advanced Glycation End product (AGE) theory
88
: 
Irreversible non enzymatic  modification of proteins, lipids and nucleic acids by 
reducing sugars and sugar derived products results in the formation of Advanced 
Glycation End products (AGE) and this reaction is called Maillard reaction. Intial 
glycation is reversible in which a sugar  non enzymatically binds  to amino groups of 
proteins, lipids and nucleic acids which results in stable Amodori products  which 
undergo further reaction to form AGE.Since this is slow process , it affects tissues 
with a slow protein turnover, like the basement membrane. Cellular effects of AGE is 
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mediated through the receptors for AGE (RAGE) which activate a number of kinases 
which results in cellular dysfunction. 
3.Protein Kinase -C theory
102
: 
Hyperglycaemia, AGE, Reactive oxygen intermediates activates Protein Kinase -
C(PKC) .Increased blood sugar levels by activating glycolytic pathway and thereby 
increasing the intracellular levels of glyceraldehyde-3-phosphate which in turn 
promotes de-novo synthesis of Diacyl glycerol(DAG) which activates protein kinase-
C aiding in the development  of diabetic retinopathy by 
 mediating the functions of VEGF. 
 Blood retinal barrier breakdown 
 Neovascular proliferation. 
4.Reactive Oxygen Intermediates theory
102
: 
Increased oxidative phosphorylation due to hyperglycaemia, auto-oxidation of 
glucose, advanced glycation end products and sorbitol pathway results in free radical 
production. Increase in the amount of free radicals results in decrease in nitric oxide 
synthetase which leads to vasoconstriction, decreased leukocyte adhesion, decrease 
endothelial cells barrier function and causes cellular proteins damage which leads to 
diabetic retinopathy. 
5.Angiogenic factors theory
102
: 
Vascular Endothelial Growth Factor(VEGF) is apeptide secreted by extravascular 
tissues like glia ,retinal pigment epithelium(RPE), macrophages and T cells and its 
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secretion is upregulated by hypoxia. It is soluble in aqueous and vitreous and it is 
potently angiogenic .It  causes 
 Breakdown of blood retinal barrier by disrupting zonula occludens 
 induces capillary endothelial proliferation resulting in neovascularisation. 
 Other factors like Insulin-like growth factors and fibroblast growth factor has 
only synergistic effect. Factors inhibiting angiogenesis are pigment epithelial 
derived factor and angiostatin ,which has a reciprocal relationship to VEGF. 
6.Insulin receptors and Glucose transporters
102
: 
The pericytes and endothelial cells of the retinal microvasculature have insulin 
receptors. These receptors are required for glucose uptake by the endothelial cells and 
insulin upregulates glycogen synthesis. Insulin may also  act as a growth factor in 
unphysiologically high concentration as seen in type 2 diabetes mellitus. 
There are 5 glucose transporters in the body, of these GLUT-1,GLUT-2,GLUT-3 are 
present in the retina.GLUT-1 in present in the endothelial cells, Retinal pigment 
epithelium , mullers cells, nerve fibre layer and in the photo receptor cell 
bodies.GLUT-2 is present in apical ends of mullers cells and GLUT-3 is found in the 
plexiform layers .It has been found that GLUT-1 concentration is increased 18 folds in 
diabetic patients which might permit greater glucose influx thereby initiating glucose 
mediated damage to the cell. 
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Newer concepts in pathogenesis: Traditionally it has been believed that the hall mark 
of diabetic retinopathy is microvascular occlusion and leakage leading to tissue 
hypoxia and edema. However newer concepts question these concepts. 
1.Extravascular changes in diabetic retinopathy
103
: 
Decreased blue-yellow colour perception, reduced oscillatory potentials on the b- 
wave of ERG and nerve fibre defects in the red free photographs in the preclinical 
stage stresses upon the fact that neurosensory dysfunction occurs long before vascular 
changes. These changes are due to abnormal glutamate metabolism resulting in 
neuronal cell death which points towards a malfunction of muller cells and astrocytes 
which are extravascular tissue. Also that VEGF is secreted by extravascular tissues 
like the retinal pigment epithelial cells, glial cells. 
2. Involvement of outer retina
103
: 
 Retinal pigment epithelium is the source of angiostatic and angiogenic factors. 
 Highest rate of metabolism of the rod photoreceptors precipitates hypoxia by 
depleting oxygen in inner retina. 
Hence rods and the retinal pigment epithelium are responsible for the earlier 
involvement of retina in diabetic microangiopathy compared to rest of the body. 
Diabetic retinopathy as an inflammatory disease
103
: 
The following points support diabetic retinopathy as an inflammatory disease 
 Presence of two signs of inflammation i.e swelling and loss of function. 
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 All microscopic signs of inflammation i.e vasodilatation, altered blood flow, 
fluid and protein exudation and leucocytosis. 
 Evidence showing the presence of leukostasis , leukocytes clogging the 
capillaries and apoptosis ,all of which is mediated by ICAM-1 
 Increased VEGF and other inflammatory mediators 
Histopathological changes occuring in diabetic retinopathy: 
1. Thickening of Capillary basement membrane:  This is caused by 
1. Glycation of capillary basement membrane collagen. 
2. decreased proteoglycan which inhibits collagen production. 
3. Vacuolization of capillary basement membrane. 
All of the above results in increased platelet adhesion, poor nutrient diffusion and 
decreased growth factor binding which are now freely circulating to induce 
angiogenesis
103
. 
2. Loss of microvascular intramural pericytes: 
Pericytes are the muscles of the capillaries which maintain their tone. As  a result of 
sorbitol accumulation and free radicals formation, the pericytes are destroyed resulting 
in the formation of microaneurysms which are focal dilatation of weakened 
capillaries. In addition capillary basement membrane is thickened which is normally 
inhibited by the pericytes
103
. 
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3.Damage to the endothelial cells: 
Capillary endothelium is damaged by the accumulation of sorbitol, Advance glycation 
end products and glucose  which is accentuated in the later stages of diabetic 
retinopathy by  the accelerated blood flow. Damage to the capillary endothelium 
results in breaching of the inner blood retinal barrier causing leakage, leukoctye  
migration and adhesion to the capillary wall with loss of its cellularity
103
. 
4.Hematological Changes:  
Following are the changes in the blood cells which results in thrombus formation in 
the capillaries and widespread retinal ischemia resulting in neovascularisation 
 RBCs which are less deformable 
 WBC which are less deformable and which are activated 
 Platelets with a tendency to aggregate easily 
 Defective fibrinolytic mechanism103. 
5.Neovascularisation: 
Neovascularisation occurs due to retinal hypoxia resulting from capillary occlusion.It 
may be intraretinal or preretinal. Intra Retinal Microvascular Abnormalities (IRMAs) 
are shunts that run from arterioles to venules within the retina. It is an attempt to 
revascularise the ischemic retina when am imbalance develops between the 
angiogenic and antiangiogenic factors
104
. 
The histopathological changes occuring in diabetic retinopathy is shown in the figure 
below 
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Figure:18 -Histopathologiacl changes in diabetic retinopathy. 
Clinical features of Diabetic Retinopathy on fundus examination: 
1.Microaneurysms: 
Microaneurysms are localised outpouchings in the capillary wall formed either  by the 
focal dilatation of capillaries where the pericytes are absent or by the fusion of two 
arms of the capillary loop and seen mainly in the inner nuclear layer where there are 
capillary non perfusion. Cellular microneurysms are formed by the endothelial cell 
proliferation due to the loss of pericytes. Hence a microaneurysms may either leak 
plasma or may be thrombosed. They are often visualised as red dots resembling dot 
haemorrhages temporal to the fovea. Hyperflouresence is seen in the early phase of 
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fundus flourescein angiography which is followed by diffuse hyperflouresence due to 
leakage in late phase
104
. 
2.Retinal haemorrhages
104
: 
 Retinal nerve fibre layer haemorrhages: arise from superficial precapillary 
arterioles and are flame shaped due to the arrangement of nerve fibre layer. 
 Intraretinal haemorrhages: are located in the compact middle layers of the 
retina and arise from the venous end of capillaries. 
 Deeper dark  round haemorrhages: which are located in the middle retinal 
layers are haemorrhagic retinal infarcts and marker of retinal 
neovascularisation. 
3.Exudates: 
Exudates are composed of lipoprotein and lipid filled macrophages in the outer 
plexiform layer and represent chronic retinal oedema .They are exacerbated by 
10
hyperlipidemia. In fundus examination they are seen as waxy yellow lesions with 
distinct borders that are seen in clumps/rings around a leaking microaneurysms in the 
posterior pole and tend to incrse with time if there is chronic leakage .If the leakge 
stops they are absorbed spontaneously. Hardexuadtes in FFA show a blocked 
flouresence
104
. 
4.Diabetic macular oedema
104
: 
This is the common cause o visual impairment among type 2 diabetics. Extensive 
capillary leakage leads to diffuse macular oedema and focal capillary leakage results 
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in focal macular oedema. The fluid is present initially between the outer plexiform and 
inner nuclear layer and later progress to involve the entire thickness of retina or may 
result in Cystoid macular oedema. Due to capillary leakage ,the macular oedema is 
seen in fundus flourescence angiogram as hyperflouresence in late phase or assumes 
as petalloid pattern if cystoid macular oedema is present. Ocular tomogram shows 
retinal thickening or cystoid spaces. It is of three types : 
 Focal maculopathy  : well circumscribed area of thickening with complete or 
incomplete ring of exudates with fundus flourescein angiogram(FFA) showing 
focal hyperflouresence with good macular perfusion. 
 Diffuse maculopathy: Severe retinal oedema  seen as diffuse retinal thickening 
obliterating the landmarks and may be associated with cystoid changes. In 
FFA, late diffuse hyperflouresence and if cystoid macular edema is present 
flower petal appearance is seen. 
 Ischemic maculopathy: Fovea appears normal with loss of vision.On 
FFA,capillary non perfusion of fovea Foveal Avascular Zone (FAZ) 
enlargement  is seen. 
5.Clinically Significant Macular Oedema
104
:  is defined according to ETDRS as 
 Thickening of the retina which is within 500 µm of the macular centre.  
 Hard exudates which is within 500 µm of the macular centre with adjacent 
thickening of the retina  which lies outside 500 µm . 
  Retinal thickening which is one or more disc diameters(1500 µm), part of 
which lies  within one disc diameter of the macular centre
104
. 
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6.Cotton wool spots: 
Cotton wool spots are microscopic infarcts of the nerve fibre layer composing of the 
neuronal debris which result from the disrupted axons with swollen ends known as 
cystoid bodies. The neuronal debris is removed by phagocytosis or autolysis. They 
are seen as small ,whitish, fluffy lesions obscuring the blood vessels in the post 
equatorial retina.FFA shows blocked fluorescence
104
. 
 
7.Venous changes
104
: 
The xtend of retina showing venous changes represents the area prone for 
neovascularisation. The venous changes seen are: 
 Generalised venous dilatation  
 Generalised venous tortuosity 
 venous looping 
 venous beading(focal narrowing and segmentation) 
8.Arterial changes: 
 Sub retinal arteriolar dilatation. 
 Peripheral narrowing of arterioles. 
 Silver wiring and obliteration of arterioles. 
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9.Intraretinal Microvascular Abnormalities:(IRMAs)are arteriolar-venous shunts that 
bypasses the capillary bed and run from the retinal arterioles to the venules adjacent 
to capillary non perfusion areas. They are seen as fine irregular ,red intraretinal lines  
that run from arterioles to venules without crossing the major vessels. In FFA, it is 
seen as focal hyperflourescence  with  adjacent capillary dropout but without 
leakage
104
. 
10.Proliferative diabetic retinopathy
104 
The main pathology behind PDR is neovascularization of retina which is an 
attempt to re-vascularize hypoxic retina. Angiogenic growth factors are elaborated by 
hypoxic retinal tissue promote neovascularization on the retina and optic nerve head 
and occasionally on the iris.Development of retinopathy is associated with the net 
balance between the activity of VEGF and endostatin. In order for PDR to develop 
more than one-quarter of the total surface area of   retina  has to be non-perfused. It 
occurs in the following forms. 
New blood vessels at optic disc (NVD) i.e neovascularization on or within one disc 
diameter of the optic nerve head .  
Newblood  vessels elsewhere (NVE) i.e neovascularization along the course of the 
major vessels.  
FFA shows hyperfluorescence during the later stages due to intense leakage of dye 
from neovascular tissue. 
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Clinical assessment : 
1. Severity of PDR is determined by the area covered with new vessels in comparison 
with the area of the disc as follows:  
 NVD is severe when more than one-third disc area in extent and mild if less  
 NVE is severe when more than half disc area in extent  and mild if less .  
2.Flat new vessels are more responsive to laser therapy than elevated vessels.  
3.Fibrous proliferation associated with neovascularization  increases risk of tractional  
4.High risk factors for severe loss of vision within 2 years, if untreated:  
 Mild NVD with haemorrhage carries a 26% risk of losing vision, which is 
reduced to 4% with treatment.  
 Severe NVD without haemorrhage carries a 26% risk of losing vision, which is 
reduced to 9% with treatment. 
  Severe NVD with haemorrhage carries a 37% risk of visual loss, which is 
reduced to 20% with treatment. retinal detachment . 
 Severe NVE with haemorrhage carries a 30% risk of visual loss, which is 
reduced to 7% with treatment..  
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Clinical features of Diabetic Retinopathy: 
  
Figure:19- showing diabetic 
fundus with microaneurysms , 
hard exudates, dot and blot 
and superficial haemorrhages. 
Figure:20- Fundus picture 
showing Cotton Wool 
Spots(black arrows)  
Figure :20- IRMAs(black arrow) 
and venous beading(white arrow) 
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Diabetic retinopathy Classification based of ETDRS modification of the 
Airlie House Classification:  
This classification evaluates seven field - thirty degree nonsimultaneous stereo colour 
fundus photographs. It is used to assess baseline status of retinopathy due to diabetes 
and progressive course of disease. This classification which is to be used in the study 
are summarized below:  
Figure:23-Showing 
neovascularisation of disc and 
neovascularistion elsewhere 
Figure:22-Clinically significant 
maculare edema with hard exudstes 
within 500μ from the center of 
fovea. 
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Disease Severity Level Findings Observable upon Dilated 
Ophthalmoscopy 
Mild nonproliferative 
retinopathy 
At least one microaneurysm 
 
AND  
 
Criteria not met for more severe retinopathy 
 
Moderate 
nonproliferative 
retinopathy 
Hemorrhages/ microaneurysms ≥ standard 
photograph 2A(Fig;25) 
 
AND/OR  
 
Cotton wool spots , venous beading, or 
intraretinal microvascular abnormalities (IRMA) 
definitely present;  
 
AND  
 
definition not met for severe retinopathy. 
 
Severe nonproliferative 
retinopathy  
Cotton Wool Spots, venous beading, and IRMAs 
definitely present in at least two of  photographic 
fields 4 to 7;  
 
OR  
 
two of the preceding three lesions present in at 
least two of fields 4 to 7 and hemorrhages and 
microaneurysms present in fields 4 to 7 > 
2A(fig:25) in at least one of them;  
 
OR 
 
IRMAs t in each of fields 4 to7 and  > 8A(fig:25) 
in at least two of them;  
 
AND  
 
definition not met for early proliferative 
retinopathy or high-risk proliferative retinopathy 
(see below) 
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Early proliferative 
retinopathy 
New vessels                         
 
AND  
 
Criteria not met for more severe retinopathy 
 
High-risk proliferative 
retinopathy 
New vessels on or within one disc diameter of the 
optic disc (NVD) ≥ standard photograph 
10A(fig:26) (about 1/4-1/3 disc area), with or 
without vitreous or preretinal hemorrhage;  
 
OR 
 
 vitreous and/or preretinal hemorrhage 
accompanied by new vessels, either NVD < 
standard photograph 10A(fig24) or new vessels 
elsewhere (NVE) ≥ one-quarter disc area 
Figure:24- Diabetic retinopathy classification
107 
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Standard fundus colour photographs for diabetic retinopathy grading 
 
 
  
Figure:25 
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Investigations: 
Fundus Fluorescein Angiography
103
: 
Though not recommended for grading diabetic retinopathy,FFA is used for guiding 
treatment of clinically significant macular oedema. Other important indications for 
FFA are 
1.Featureless retina: In clinical scenarios where new vessels are present without 
evidence of severe NPDR or presence of white thread like arterioles in mild 
NPDR,FFA may reveal the presence of unsuspected new vessels and also extensive 
capillary non perfusion. 
2.Asymetrical diabetic retinopathy: where the fellow eye has proliferative diabetic 
retinopathy, FFA picks up hidden new vessels. 
3.Macular ischemia: suspected macular oedema due to clinical features like subnormal 
vision, sclerosed macular arterioles,blot hamorrhages and soft exudates at the macula 
can be confirmed by FFA. 
Figure:26:Standard photograph 
10A:Neovascularisation of disc. 
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4.Poor visibility due to asteroid hyalosis. 
5.To differentiate severe NPDR from PDR:In severe NPDR, non leaking IRMAs are 
seen  along with extensive capillary drop outs in contrast to PDR where leaking new 
vessels are seen in FFA. 
6.To confirm diabetic papillopathy: where in FFA, vascular filling defects of the disc 
and choroid are absent unlike Non arteritic AION and late leakage of disc is 
intramural unlike that of neovascularisation of the disc.  
Salient features of diabetic retinopathy in FFA: 
1.Mid-aretriovenous phase or capillary phase: clinical features visible are 
 Capillary non perfusion areas. 
 Macular ischemia characterised by enlargement of foveal avascular zone, 
irregularity of the borders of foveal avascular zone. 
 Leaking microaneurysms which can be differentiated from solid 
microaneurysms and dot haemorrhages. 
 IRMA s which do not leak can be differentiated from new vessels which leak. 
2.Late phase: 
 Intraretinal haemorrhages become prominent and pre retinal and intravitreal 
leaks from the new vessels give a classic cotton ball hyperflourescence. 
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B mode ultrasonogram
103
: 
 in advanced diabetic retinopathy with opaque media. 
 Gives information about the macular status and the extend of posterior vitreous 
detachment, retinal detachment and areas of traction. 
Optical Coherence Tomography
103
: 
OCT is based on the principle of interference of reflected infra red rays from the 
tissue.The OCT gives a high resolution histopathological view of the macula and are 
therefore primary tool of macular assessment .It is used to assess the role of 
vitreomacular traction and hence the need for laser photocoagulation and as 
alternative for FFA to asses and follow up CSME .However neither the sites of 
leakage  as in FFA nor the macular status in opaque media as in USG can be assesd 
using OCT and it is always an alternative to the above two. 
 
Figure:27 Late  FFA picture showing 
diffuse leakage in CSME 
Figure:28 FFA showing leakage from 
new vessels. 
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Electroretinogram
103
: 
Used only as research tool .Abnormalities in oscillatory potential precedes the 
vascular changes in diabetic retinopathy. Multifocal ERG is records responses from 
individual areas and hence used to predict focal retinal areas that would develop 
edema. 
Management of diabetic retinopathy: 
Diabetic control: 
Unless the systemic diabetes is under control, one cannot treat or impede the 
progression of diabetic retinopathy. The few of treatment of diabetes are as follows: 
1.Insulin therapy: 
 
 Rapid acting preparations   
  Intermediate acting preparations  
  Long acting preparations  
  Human Insulin 
2.Diet therapy: 35kcal/kg body weight/day and 0.8-1gm protein/kg body weight/day 
and  fat content to be 30% or less of total calories with saturated fat - 7-10%. 
3.Exercise therapy. 
4.Oral hypoglycemics: 
  
• Sulphonyl ureas –Glipizide, Glimepride, Glyburide 
• Biguanides – Metformin 
• Meglitinides – Nateglinide, Repaglinide 
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• Thiazolidinediones – Pioglitazone, Rosiglitazone 
• Glucosidase Inhibitors – Acarbose, Miglitol  
• DPP-IV Inhibitors - Sitagliptin  
Also the ophthalmologist should make sure the diabetic patients HbA1C is maintained 
close to 7g/dl, blood pressue close to 130/80  mm Hg, total cholesterol within 200 
mg/dl and haemoglobin >13g/dl with no traces of protein in urine. 
Management of different grades of Diabetic Retinopathy : 
Grades of  Diabetic Retinopathy Management. 
No diabetic retinopathy Review every 12 months 
Very mild NPDR :  
Microaneurysms only 
Review every 12 months 
Mild NPDR Review range 6-12 months, depending 
on severity of signs, stability, systemic 
factors, patient’s personal 
circumstances 
Moderate NPDR Review in approximately 6 months 
Severe NPDR Review in 4 months 
Very Severe NPDR 
2 or more of the criteria for severe 
Review in 2-3 months 
Low risk PDR Customize the treatment according to the 
patient, if not treated review in 2 months. 
High risk PDR Immediate treatment. 
Advanced diabetic eye disease: 
Tractional retinal detachment, 
Vitreous hemorrhage and neovascular 
glaucoma 
Immediate treatment. 
Figure:29:Different grades of diabetic retinopathy treatment
104
. 
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Treatment specific for Diabetic Retinopathy 
 Laser Photocoagulation 
 Surgical – Vitrectomy, Intravitreal injections 
 
Laser photocoagulation
103
: 
Mechanism of action: 
Laser increases the temperature of the tissue to about 20
0
 C ,thereby causing 
coagulative necrosis and intracellular protein denaturation resulting in 
photocoagulation. The target is melanin pigment in RPE and haemoglobin in 
capillaries and microaneurysms. In PDR, laser treatment converts the hypoxic retina 
into anoxic retina thereby decreasing the release of angiogenic factors and also 
increases oxygen supply to inner retina by destroying the RPE and photoreceptors. 
Laser induced debridement of RPE induces reproliferation of both inner and outer 
retianl barrier and therefore better function resulting resolution of macular edema. 
Laser Wavelength selection: 
Argon green(514 nm),Nd:YAG(green,532nm),Dye yellow(577 nm), Kryton 
Red(647nm) and diode (infrared 812 nm) can be used for both macular edema and 
proliferative diabetic retinopathy. However Argon blue-green is contraindicated in 
macular edema. 
Modes of laser delivery: 
• Using slit lamp using standard goldmann 3 mirror lens or a panfundoscope. 
73 
 
• Indirect ophthalmoscopic laser delivery method. 
• Endoscopic laser delivery using fibreoptic tubes during vitrectomy. 
• Transscleral diode laser for cyclocoagulation in neovascular glaucoma. 
Indications: 
1.Clinically significant macular edema 
 Grid laser-  for diffuse leakage 
 Focal laser- for focal leakage 
2.Paramacular edema 
3.Early/high risk proliferative diabetic retinopathy. 
4.Severe/very severe Non Proliferative Diabetic Retinopathy-in case of poor 
compliance, fellow eye with proliferative diabetic retinopathy, other uncontrolled 
systemic diseases, pregnancy, pending cataract surgery, uncontrolled diabetes. 
  
Figure:30- Fundus picture fresh laser marks of 
scatter retinal photocoagulation 
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Parameters: ETDRS protocol for Pan Retinal Photocoagulation105 
Spot size  500microns 
Exposure time  0.1s 
Intensity  Moderate 
Number of shots  1200 – 1600 
Location  
 
Diameter of shot separation, >2DD out 
of fovea to the equator 
Number of sessions  At least 2 
Treated lesions directly  New vessels which  2DD in 
extrapapillary location 
Indications for new treatment  
 
Areas of new vessels  in the 
extrapapillary region , high risk 
PDR, recurrence 
 
Figure:31-ETDRS Pan retinal photocoagulation protocol. 
 
Figure:32- Different patterns of laser photocoagulation. 
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Modified ETDRS protocol for focal /grid photocoagulation  in CSME
102 
Treatment parameter Focal laser  Grid laser 
Area treated 500-3000μ from the 
centre of the macula 
500-3000μ superiorly ,nasally 
and inferiorly from the macular 
centre. 
500-3500 μ from the macular 
centre. not within 500μ of disc.  
Spot size 50μ 50μ with two burn width apart 
with barely visible burn 
intensity. 
Burn duration 0.05to 0.1 seconds 0.05-0.1 seconds 
Figure:33-ETDRS photocoagulation protocol for CSME. 
Side effects: 
A. After laser treatment of Diabetic macular edema: 
1. Transient increase in edema. 
2. Paracentral scotomas. 
3. Photocoagulation scar expansion 
4. Inadvertant foveolar burns. 
5. sub retinal fibrosis 
6. Choroidal neovascular membranes. 
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B. After panretinal photocoagulation: 
1. Peripheral field loss. 
2. Macular edema. 
3. Pain 
4. Pre-retinal fibrosis/ Tractional Retinal detachment. 
5. Choroidal detachment 
Surgical Treatment: 
Vitrectomy
103
: 
When optimal glucose control and photocoagulation fails to stop the progression of 
diabetic retinopathy then one should consider Pars plana vitrectomy. Whenever 
possible pan retinal photocoagulation should be done before doing pars plana 
vitrectomy. 
Indications: 
1. Chronic persistant vitreous haemorrhage. 
2.  Epimacular membrane 
3. Tractional retinal detachment involving the macula. 
4. Neovascularisation not responding to photocoagulation 
5. Rhegmatogenous retinal detachment alone or if complicating a tractional 
retinal detachment. 
6. Diabetic macular edema caused by vitreo macular traction. 
7. Rarely in neovascular glaucoma to clear media opacities before giving PRP. 
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Objectives and techniques: 
 Removal of vitreous opacities. 
 Removal of anteroposterior and tangential vitreoretinal and epiretinal 
membrane induced traction. 
-Segmentation technique to relieve antero posterior traction 
-Delamination technique to remove tangential traction. 
Intravitreal injections
102
: 
Anti-VEGF: 
1. Bevacizumab (Avastin): is 149 kD full-length, humanized, monoclonal recombinant 
antibody  against VEGF isoforms  , it also blocks VEGFR tyrosine kinase receptors in the 
endothelial cells  and thereby inhibits neovascularisation and vascular leakage .It's dose  
intravitreally is1.25 mg/0.05 ml. It has been prove to decrease the OCT macular thickness 
and improves vision. However it increases systemic blood pressure. 
 
2. Ranbizumab(Lucentis):It is affinity matured humanized  48 kD, monoclonal 
recombinant antibody fragment .It is given in a dose of 0.5 mg/0.05 ml intravitreally. 
3.Pegatinib(Lucentis): It is a 28 kD RNA pegylated aptamer and specifically blocks 
VEGF-165 isoforms and given in adose of 0.3mg/0.09ml intravitreally. However it 
lacks the efficacy of Avastin and Lucentis.  
4.VEGF trap:It is formed by the fusion of  ligand binding elements of VEGF receptor 
extracellular components and Fc portion of IgG1. 
 
78 
 
Steroids:Intravitreal Triamcinolone  injection is given to treat diabetic macular edema 
not responding to focal or grid laser photocoagulation. It is given in a dose of 4mg in 
0.1 ml . It predisposes the patient to increased intraocular pressure. 
Eye Examination protocol for early detection of diabetic retinopathy
106
: 
Type of diabetes Recommended initial eye 
examination 
Routine follow up 
Type 1 5 years after onset or 
during puberty 
Yearly. 
Type 2 At time of diagnosis Yearly. 
Pregnancy with pre-
existing Diabetes 
mellitus 
Prior to pregnancy for 
counselling 
Early in 1st trimester. 
Each trimester  or more 
frequently 
Six weeks postpartum 
Figure 34:Eye examination protocols for diabetics. 
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Materials and Methods 
 It is a  prospective descriptive analytical study 
 Study population: 
This is a hospital based study involving a cross section of  inpatients and 
outpatients of Ophthalmology department of   PSG Hospitals with clinical 
diagnosis of Type 2 diabetic retinopathy over a period of 12 months from June 
2012 to June 2013. 
 
 Inclusion criteria: 
1. Type 2 Diabetes With retinopathy 
2. ≥40 years of age 
3. Duration of diabetes more than 5 years. 
 
 Exclusion criteria: 
1. Type 1 Diabetes 
2. <40 years of age 
3. other  retinal disease  
4. Type 2 diabetes  without retinopathy 
5. Terminally ill patients 
 Sample size: 
Due to money and time constraint  convenient  sample of 100  patients with  
type 2 diabetic retinopathy are  included in this study. 
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 Study design: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
    Type 2 Diabetic patients attending PSGIMSR  Ophthalmology OPD   
Evaluation using 90D slit lamp biomicroscopy/Indirect 
ophthalmoscpoe 
   
          
 100 Patients  with T2D Retinopathy 
Informed consent 
 30
0  
 7 field fundus photograph and grading with ETDRS classification. 
 
Gene analysis with 2 ml of blood ICAM 1 K469E Polymorphism 
using  PCR RFLP 
                Result analysis 
 
            Categorised as Sight Threatening Diabetic Retinopathy  
                & Non- Sight threatening Diabetic retinopathy  
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 Methodology: 
 Type 2 diabetic patients are evaluated for the presence of retinopathy by using 
90D slit lamp biomicroscopy 20 D and with indirect opthalomoscopy for the 
presence of diabetic retinopathy 
 Type 2 diabetic patients with retinopathy who fit into the inclusion criteria are 
selected. 
 300 7 field colour fundus photographs are taken .The area to be covered in each 
field is as follows: 
 Field 1: Optic disc; the intersection of the mires is at the optic disc 
centre. 
 Field 2: Macula; the intersection of the mires is at the macula. 
 Field 3:Temporal to the macula; the field is so positioned that the 
macula lies in the nasal edge of this field. 
 Field 4: Superior temporal; a horizontal line which pass through the 
superior optic disc border is tangential to this fields lower edge and  a 
vertical line through the optic disc centre is tangential to its  nasal edge. 
 Field 5:Inferior temporal; a horizontal line which pass through the 
inferior optic disc border is tangential to this fields upper edge and  a 
vertical line through the optic disc centre is tangential to its  nasal edge. 
 Field 6: Superior Nasal; a horizontal line which pass through the 
superior optic disc border is tangential to this fields lower edge and  a 
vertical line through the optic disc centre is tangential to its  temporal 
edge. 
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 Field 7:Inferior nasal; a horizontal line which pass through the inferior 
optic disc border is tangential to this fields upper edge and  a vertical 
line through the optic disc centre is tangential to its temporal edge.  
 
 
 
Fig:36-Fields 1,2,3 of the ETDRS 7 field fundus photographs for Diabetic Retinopathy 
grading 
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 Their diabetic retinopathy graded according to ETDRS modification of the 
Airlie House Classification by comparing the photographs taken with standard 
ETDRS colour photographs 2A,6A,8A,10A and grading done independently by 
three ophthalmologists 
 25 patients each having mild ,moderate ,severe and proliferative diabetic 
retinopathy respectively are enrolled  in the study which accounts for the total 
sample size of 100. 
 For convenience purpose early PDR and high risk PDR are clubbed together 
into a single group called "Proliferative Diabetic Retinopathy" 
 These 4 categories are further divided  into 2 groups namely Non-Sight 
Threatening Diabetic Retinopathy (NSTDR) and Sight Threatening Diabetic 
Retinopathy  (STDR) depending upon the course of the grade of retinopathy to 
cause defective vision in the near future. 
 Sight Threatening Diabetic Retinopathy(STDR) is defined as those with Severe 
Diabetic Retinopathy, Proliferative Diabetic Retinopathy and any Diabetic 
Retinopathy with Clinically Significant Macular Edema 
 Non Sight Threatening Retinopathy is defined as those with Mild and Moderate 
Diabetic Retinopathy 
 2ml of blood is drawn from each of these patients for the gene anlaysis to 
determine the presence of ICAM 1 K469E Polymorphism. 
 Gene analysis:  
 Extract DNA from the peripheral blood samples by conventional phenol 
chloroform method .  
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 The genomic region flanking the K469E polymorphism in exon 6 of ICAM-
1 amplified with forward (50 -CTTGAGGGCACCTACCTCTG-30 ) and 
reverse on(50 -CATTATGACTGCGGCTGCTA-30 ) using PCR . 
 RFLP will be done to identify the mutation 
 Data so obtained is entered in the excel sheet and statistically analysed using 
SPSS software. 
 
DNA CHECK
 
Figure:37 DNA Extraction 
                                                            PCR CHECK 
 
 
Figure:38  PCR to amplify the gene 
STEPS IN GENE ANALYSIS 
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Figure 39:using restriction enzyme BstUI  to identify the Single nucleotide polymorphism. 
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RESULTS 
Demographic Profile of the study population: 
1.Age distribution of the study population: 
 
Figure 40:-Age distribution of the study population. 
In this study only patients who had been diagnosed with diabetes after 40 years were 
included to exclude patients with Type 1 diabetes which has its onset before 30 years 
of age. Majority of the study population in this study were in the age group 51-60 
years as seen from the pie chart above. 
 
22%
42%
31%
5%
Age Distribution
40-50 yrs 51-60 yrs 61-70 yrs 71-80 yrs
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Sex Distribution: 
 
 
Figure 41: Sex Distribution of the study population. 
Among the 100 Type 2 diabetic patients involved in my study,77% were males and 
23% were  females as shown in the pie chart above. 
 
 
 
Females
23%
Males
77%
Sex Distribution
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Duration of Diabetes among study population: 
 
 
Figure:42-Diabetic duration among study population 
In this study only patients who are older than 40 years and have Type 2 diabetes for 
more than 5 years are included. Of the 100 patients studied majority (35%) had 
diabetic duration within the range of 5-10 years. 
 
 
 
5-10 yrs 11-15 yrs 16-20yrs 21-25yrs 26-30 yrs >30yrs
35%
24%
16%
9%
14%
2%
Percentage of study population with different  duration of  
diabetes
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Treatment for Type 2 diabetes among the study population: 
Majority of the study population were on treatment with oral glycemics for blood 
sugar control. Only 29% were on insulin treatment for Type 2 diabetes . None of them 
were on diet control only. 
 
Figure:43:Treatment of Type 2 diabetes among the study population. 
 
  
On OHAs, 71%
On Insulin
29%
Treatment of Type 2 Diabetes Mellitus
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Presence of other co-morbidities among the study population: 
In our study , almost half of the patients with Type Diabetic Retinopathy had no 
co-morbidities and the other half had co morbidities. Other co-morbidities 
associated with diabetic retinopathy type 2 include systemic hypertension , 
Cerebrovascular accident ,Ischemic vascular diseases, Peripheral Vascular 
Diseases etc. The percentage of study population with and without  co-
morbidities is shown in the picture chart below. 
 
 
No comorbidities
48%
Presence of 
comorbidities
52%
Percentage of study population with and without 
comorbidities
Figure 44:Presence  of comorbidities among study 
population 
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Severity of Diabetic Retinopathy among study population: 
After grading the patients with diabetic retinopathy  according to ETDRS 
classification, Early and High risk proliferative diabetic retinopathy has been clubbed 
into a single category as "Proliferative Diabetic Retinopathy", thereby  making up to 4 
categories in this study namely Mild Non Proliferative Diabetic Retinopathy group, 
Moderate Non Proliferative Diabetic Retinopathy group, Severe Non Proliferative 
Diabetic Retinopathy group and Proliferative Diabetic Retinopathy group. 
In our study we enrolled 25 patients in each category .Incidence of CSME  in our 
group was 9%.7 patients in the Severe NPDR group had CSME and one patient in 
each of the Mild and Moderate NPDR group had CSME. Among the 25 patients in the 
Proliferative Diabetic Retinopathy group ,only 3 had high risk characteristics. 
 
Frequencies of different grades of Diabetic Retinopathy among different 
age groups
 
 
36%
12%
36%
20%
23%
33%
13%
40%
14%
31%
22%
40%
27%
24%
29%
40-50 yrs 51-60yrs 61-70 yrs 71-80 yrs
Diabetic  Retinopathy Frequency among different age 
groups
Mild NPDR Moderate NPDR Severe NPDR PDR
Figure 45: Frequencies of different grades of Diabetic Retinopathy 
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Different grades of diabetic retinopathy is somewhat equally distributed among all the 
age groups and there was no statistically significant relation between them . 
 
Gender differences in the frequency of diabetic retinopathy: 
 
Figure 46:Gender differences in diabetic retinopathy frequency 
 
There was no statistically significant relationship between  severity of diabetic  
retinopathy and the gender differences. 
26%
28%
13%
29%
44%
20%
17%
27%
Female Male
Gender differences in diabetic retinopathy frequency
Mild NPDR Moderate NPDR Severe NPDR PDR
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Prevalence of Sight threatening Retinopathy among the study population: 
 
Figure 47:Prevalence of Sight Threatening and Non Sight Threatening Diabetic Retinopathy among the study 
population. 
In our study, 25 patients had Proliferative Diabetic Retinopathy ,25 patients had 
Severe Non Proliferative Diabetic Retinopathy and 2 patients outside these two groups 
had Clinically Significant Macular Edema accounting for the 52% prevalence of Sight 
Threatening Diabetic Retinopathy . 
46%
47%
48%
49%
50%
51%
52%
Non Sight Treatening Diabetic 
Retinopathy
Sight Threatening Diabetic 
Retinopathy
48%
52%
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Gender differences among Sight Threatening and Non Sight Threatening 
Diabetic Retinopathy: 
 
Figure:48:Gender distribution among Sight Threatening Diabetic Retinopathy(STDR) and Non Sight 
Threatening Diabetic Retinopathy(NSTDR) 
 
The males constituted 81.25%   among Non sight threatening  daibetic retinopathy and 
73% of those with sight threatening diabetic retinopathy. 
 
 
0.00%
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40.00%
60.00%
80.00%
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SDTR
   81%
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Insulin requirement among patients with  Sight Threatening Diabetic 
Retinopathy(STDR) and Non Sight Threatening Diabetic Retinopathy 
(NSTDR) 
 
Figure:49: Insulin requirement among patients with Sight Threatening Diabetic 
Retinopathy(STDR) and Non Sight Threatening Diabetic Retinopathy(NSTDR). 
 
The above graph depicts that insulin requirement among the Sight Threatening 
Diabetic Retinopathy(STDR) is 61.54%  which is less than insulin requirement among 
those with Non Sight Threatening Diabetic Retinopathy (NSTDR)(75%). 
 
0%
20%
40%
60%
80%
100%
NSTDR
STDR
25% 38.46%
75% 61.54%
REQUIRES INSULIN DOESNT REQUIRE INSULIN.
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Co existing co-morbidities among patients with  Sight Threatening Diabetic 
Retinopathy(STDR) and Non Sight Threatening Diabetic Retinopathy (NSTDR) 
 
 
Figure 50:Co-morbidities among those with Sight Threatening Diabetic Retinopathy(STDR) 
and Non Sight Threatening Diabetic Retinopathy (NSTDR) 
 
46.16% of those people with Sight Threatening Diabetic Retinopathy(STDR) and  
45.84% of those with Non Sight Threatening Diabetic Retinopathy (NSTDR) had co-
morbidities. 
 
NSTDR
STDR
54.16%
53.84%
45.84%
46.16%
CASES WITH COMORBIDITIES CASES WITHOUT COMORBIDITIES
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Distribution ICAM-1 K469E Polymorphism among the study population. 
 
 
 
Figure 51:Distribution of ICAM-1 K469 E polymorphism among study population. 
The heterozygous AG genotype was more common among the study population  with 
a prevalence of  56% followed by AA genotype with a prevalence of  25% and then 
GG with a prevalence of  21%  
 
AA
25%
AG
56%
GG
21%
ICAM-1K469E Polymorphism
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Distribution  of ICAM-1 K469E Polymorphism among patients with  Sight 
Threatening Diabetic Retinopathy(STDR) and Non Sight Threatening 
Diabetic Retinopathy (NSTDR). 
 
  
 
Figure:52: ICAM-1 K469E Polymorphism among patients with  Sight Threatening Diabetic Retinopathy 
(STDR) and Non Sight Threatening Diabetic Retinopathy (NSTDR).patients with  Sight Threatening Diabetic 
Retinopathy (STDR) and Non Sight Threatening Diabetic Retinopathy (NSTDR
NSTDR
STDR
22.90%
26.90%
54.20%
53.80%
22.90%
19.30%
AA AG GG
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Table 35: FEATURES OF THE PATIENTS IN THE STUDY: 
Characteristics NSTDR STDR P value 
Age(years) 59.02 + 7.8 59.35+6 0.815 
Males(n,%) 39(81.25) 38(73.07) 0.334 
Duration(years) 10.79+8.3 11.90+5.4 0.434 
Co-morbidities(n,%) 26(54.16) 28(53.84) 0.975 
Eye  manifestations(n,%)
$ 
20(60.42) 42(80.76) 0.026* 
Insulin requirement(n,%) 12(25) 20(38.46) 0.151 
FBS (mg/dl) 160.2+57.14 175.56+71.073 0.236 
HbA1c(%) 8.14+2.15 8.26+1.94 0.151 
 
$
Presence of Ocular manifestation of diabetes other than retinopathy  with M+ SD .* p<0.05 which  is statistically significant.  
FBS- Fasting blood sugar; HbA1c-Glycosylated Haemoglobin; ICAM-1-Intercellular Adhesion Molecule, STDR-Sight Threatening Diabetic Retinopathy ; NSTDR-Non 
Sight Threatening Diabetic Retinopathy. 
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Table 36:Distribution of ICAM-1 K 469E polymorphism among non sight threatening and sight threatening 
retinopathy 
 
Genotypes NSTDR STDR P value 
AA (n,%) 11(22.9) 14(26.9) 0.640 
AG(n,%) 26(54.2) 28(53.8) 0.974 
GG(n,%) 11(22.9) 10(19.3) 0.651 
A Allele(n,%) 48(50) 56(53.9)  
G allele( n,%) 48(50) 48(46.1) 0.5713 
 
STDR-Sight Threatening Diabetic Retinopathy ; NSTDR-Non Sight Threatening Diabetic Retinopathy. ICAM-1-Intercellular Adhesion Molecule 
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Table 37:Logistic regression analysis of  NSTDR and STDR groups among the ICAM -1 K469E Polymorphism 
genotypes and various clinical variables keeping severity of diabetic retinopathy as the dependant factor: 
Clinical Variables AA AG GG 
OR( 95% CI) p OR( 95% CI) P OR(95% CI) P 
Age 1.031(0.93 to 1.178) 0.651 1.001 (0.926 to 1.081) 0.981 1.006 (0.898 to 1.126) 0.921 
Sex 1.227(0.167 to 9.017) 0.840 0.540 (0.163 to 1.785) 0.313 0.900 (0.49 to 16.594) 0.944 
 Diabetes Duration 1.016(0.869 to 1.188) 0.839 1.030 (0.955 to 1.111) 0.444 1.010 (0.904 to 1.128) 0.866 
Co- morbidities 0.625 (0.127 to 3.066) 0.562 1.035 (0.346 to 3.095) 0.951 1.944(0.322 to 11.756) 0.469 
Eye manifestations
$ 0.333(0.063 to 1.752) 0.194 0.194 (0.052 to 0.720) 0.014* 2.500(0.191 to 32.802) 0.485 
Insulin requirement 0.133(0.013 to 1.346) 0.088 0.317  (0.093 to 1.085) 0.67 4.8(0.682 to 33.798) 0.115 
FBS 0.999 (0.989 to 1.008 0.804 1.003 (0.993 to 1.013) 0.537 1.016(1.000 to 1.034) 0.56 
HbA1c 0.894(0.607 to 1.317) 0.570 0.933 (0.721 to 1.207) 0.599 1.960(1.076 to 3.570) 0.028* 
 
$
 Presence of Ocular manifestation of diabetes other than retinopathy.* p<0.05 which  is statistically significant.  
FBS- Fasting blood sugar; HbA1c-Glycosylated Haemoglobin; ICAM-1-Intercellular Adhesion Molecule 
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Table 38:Logistic Regression  analysis of the STDR group with sequential addition of clinical covariates and ICAM -
1 K469E Polymorphism genotypes as dependent variable. 
Clinical Variables AA Vs AG AA Vs GG GG Vs AG 
OR(95% CI) p OR( 95% CI) p OR( 95% CI) P 
Unadjusted 1.182 (0.456 to 3.066) 
 
0.731 1.400(0.437 to 4.488) 0.571 0.844(0.308 to 2.316) 0.742 
Age 1.192 (0.458 to 3.102) 
 
0.718 1.422(0.441 to 4.582) 0.555 0.844(0.308 to 2.316) 0.742 
Age+ Gender 1.251 (0.476 to 3.289) 0.649 1.399(0.429 to 4.563 0.578 0.940 (0.334 to 2.650) 0.907 
Age + Gender +DD 1.228 (0.465 to 3.242) 
 
0.678 1.364 ( 0.403 to 4.613) 0.618 0.982 (0.344 to 2.8) 0.973 
Age + Gender +DD + 
Insulin 
1.272 (0.468 to 3.460) 0.637 1.375(0.405 to 4.670) 0.610 1.004(0.347 to 2.902) 0.994 
Age + Gender +DD+ 
Insulin + FBS 
1.265 (0.464 to 3.447) 
 
0.646 1.431(0.413 to 4.959) 0.572 0.902(0.301 to 2.698) 0.853 
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Age + Gender +DD + 
Insulin +FBS+ HbA1c 
1.248 (0.454 to 3.430) 0.668 1.437(0.414 to 4.989) 0.568 0.902(0.302 to 2.701) 0.854 
Age + Gender +DD+ 
Insulin +FBS+ HbA1c+ 
co- morbidities 
1.246 (0.453 to 3.428) 
 
0.670 1.413(0.397 to 5.027) 0.594 0.885(0.285 to 2.748) 0.833 
Age + Gender +DD + 
Insulin +FBS+ HbA1c+ 
co- morbidities+ Eye 
manifestations 
1.440(0.501 to 4.138) 0.499 1.579(0.420 to 5.930) 0.499 0.753(0.233 to 2.436) 0.636 
 
DD- Diabetes Duration; FBS- Fasting blood sugar; HbA1c-Glycosylated Haemoglobin; ICAM-1- Intercellular Adhesion Molecule. 
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Result analysis of the Tables 35-38: 
 Table 35:shows the baseline characteristic of the study population among Non 
sight threatening diabetic retinopathy  and sight threatening diabetic 
retinopathy with their statistical significance. Only ocular manifestations of 
diabetes other than retinopathy had p value <0.05 and was significantly 
associated with sight threatening diabetic retinopathy. 
 
 Table 34: shows the frequency  distribution of genotypes and alleles of  
ICAM-1 polymorphism among Non sight threatening diabetic retinopathy  and 
sight threatening diabetic retinopathy with their statistical significance. There 
was no statistically significant association between them . 
 
 Table 35: Logistic regression analysis of  NSTDR and STDR groups among 
the ICAM -1 K469E Polymorphism genotypes and various clinical variables 
keeping severity of diabetic retinopathy as the dependant factor. However in 
the table only the odds ratio and p value of sight threatening retinopathy is 
shown.AG genotype of ICAM-1K469E polymorphism  among the STDR 
group is significantly associated  with other ocular manifestation with a p value 
of 0.014. Elevated HbA1c among  AG genotype of ICAM-1K469E 
polymorphism  is signifacntly associted with sight threatening retinopathy with 
a p value of 0.028. 
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 Table 38: Logistic Regression  analysis of the STDR group with sequential 
addition of clinical covariates and ICAM -1 K469E Polymorphism genotypes 
as dependent variable. Here AA genotype is considered normal and taken as 
the reference group. However in  GG Vs AG,GG is considered the reference 
group. Unadjusted analysis id done between the sight threatening diabetic 
retinopathy  as independent variable and genotype as the dependent variable 
.Then other clinical covariates are sequentially added. 
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Discussion: 
Our study population consisted of 100 patients with diabetic retinopathy who were 
classified into  four groups of 25 each depending upon the severity of diabetic 
retinopathy. The diabetic retinopathy severity is determined using the  ETDRS  
Classification of 30 degree 7 field fundus photograph. In our study, only 9% had 
Clinically Significant Macular Edema (CSME) as determined by ETDRS. Among the 
25 patients with proliferative diabetic retinopathy, only 4 patients had high risk 
characters like vitreous haemorrhage, Retinal detachment, post PRP un stable PDR. 
 
In this study, Sight Threatening Diabetic Retinopathy is defined as presence of 
proliferative diabetic retinopathy or severe non proliferative diabetic retinopathy or 
presence of clinically significant macular edema. Non sight threatening retinopathy is 
defined as the presence of either mild or moderate non proliferative diabetic 
retinopathy
108
. The  overall prevalence of sight threatening diabetic retinopathy among 
the study population is 52% and the prevalence of Non Sight diabetic Threatening 
Retinopathy among the study population is 48%. 
 
The mean age of the study population with  Sight Threatening Diabetic Retinopathy is 
59.35+6 years while that of  those with Non Sight Threatening Diabetic Retinopathy 
is 59.02 + 7.8 years. Thus the mean age of both the groups are the same thereby 
eliminating the confounding effect of age on the severity of diabetic retinopathy.  
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Majority of the study population were males(77%) constituting 81.25% of those with 
Non Sight Diabetic Threatening and 73.07% of those with Sight Threatening Diabetic 
Retinopathy. However this slightly high prevalence of Non Sight Threatening 
Diabetic Retinopathy among male gender was not statistically significant. This 
observation in our study is supported by Wisconsin Epidemiologic Diabetic 
Retinopathy(WESDR) where it is proved that there is no association between the sex 
and the incidence and progression of Type 2 Diabetic Retinopathy
67
. However in  
studies done in South India  proved  that men are at greater risk than women in 
developing diabetic retinopathy
108
.  
 
The mean duration of diabetes among the patients with Sight Threatening Diabetic 
Retinopathy is 11.90+5.4 years which is  only marginally more than the mean duration 
of diabetic among patients with Non Sight Threatening Diabetic Retinopathy which is 
10.79+8.3 years. This means that the severity of diabetic retinopathy is not affected by 
the duration of diabetes among the study population. However studies in  South 
India
108
 show that the severity of diabetic retinopathy increases as the duration of 
diabetes increases which is also supported by  international studies like WESDR 
67
 . 
The role of duration of Type 2 diabetes in determining the severity of diabetic 
retinopathy is lacking in this study population  mainly due to the fact that most 
patients are uncertain about their onset of diabetes and also few have their Type 2 
diabetes diagnosed only after they develop complications due to diabetes like 
nephropathy, retinopathy etc.  
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Presence of Co-morbidities like hypertension, Cerebral Vascular Accidents, Peripheral 
Vascular Diseases, Nephropathy, Ischemic heart disease, anaemia etc worsen the 
severity of diabetic retinopathy
67
. In our study, the contributions from the coexisting 
co-morbidities to worsen the diabetic retinopathy is missing with only 54.16% of 
patients with Non Sight Threatening Diabetic Retinopathy and 53.84% of patients 
with Sight Threatening Diabetic Retinopathy having co-morbidities. 
 
Ocular manifestations due to diabetes other than retinopathy among our study 
population is significantly greater among those with Sight Threatening Diabetic 
Retinopathy  compared to those with Non Sight Threatening Diabetic Retinopathy. 
This observation can be substantiated by the fact factors like uncontrolled blood sugar, 
prolonged diabetic duration ,genetic variations predisposing patient to severe  Sight 
threatening diabetic retinopathy may also predispose them to other microvascular 
complications resulting in extraocular motility disturbances, Open angle glaucoma and 
also metabolic disturbances that leads to lens changes. 
 
Percentage of patients requiring insulin  among the sight threatening diabetic 
retinopathy  group was 38.46% as compared to only 25% requiring insulin among the 
Non sight threatening diabetic retinopathy group but however the difference in the 
insulin requirement between the two groups was not statistically significant. This was 
similar to the WESDR study where no association was found between the requirement 
of exogenous insulin and the severity of diabetic retinopathy
67
. But in a recent study 
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done in rural South India, it has been found out that  use of insulin  is linked up with 
increased diabetic retinopathy risk
108
. 
 
Though the mean Fasting Blood Sugar (FBS) levels are slightly higher among the 
patients with Sight Threatening Diabetic retinopathy compared to those with Non 
Sight Threatening Diabetic Retinopathy, this difference was not clinically significant. 
This is similar to a  study done in South India which no relationship between the 
levels of fasting blood glucose and incidence and severity of diabetic retinopathy
109
. 
However according to studies like The Diabetic Control and Complications Trial 
(DCCT)
68
 and the United Kingdom Prospective Diabetes Study Group(UKPDS)
69
 , 
the progression of diabetic retinopathy is retarded by tight glycemic control. 
 
The mean glycosylated haemoglobin levels among patients with Non Sight 
Threatening Diabetic Retinopathy and Sight Threatening Diabetic retinopathy are 
similar .In our study the progression of diabetic retinopathy to sight threatening type is 
not influenced by glycosylated haemoglobin. This is in contrast to the  results of 
WESDR study where a significant increase in the proliferative type of diabetic 
retinopathy was associated with elevated glycosylated haemoglobin levels
70
. 
 
Three different genotypes as a result of ICAM-1 K469E  polymorphism noted  in our 
study population  are AA,AG,GG. Of these AA is the wild type one which is present 
in majority of the population. The presence of G allele in place of one A or both A 
alleles result in heterozygous or homozygous gene mutant.GG is the recessive 
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genotype present only in small proportion of the population  and responsible for 
certain diseases. 
 
The frequency distribution of AA,AG and GG in our study population is 
25%,56%,21% respectively .The genotype distribution  in our study is quite similar to 
the genotype composition among the patients with diabetic retinopathy in a study 
conducted by Sankara Nethralaya  where the frequencies of AA,AG,GG were 
30.2%,46.2% and 23.6% respectively
97
. 
 
Among the patients with Non Sight Threatening Diabetic Retinopathy,22.9% had AA 
genotype,56.2% AG genotype and 22.9% had GG genotype. The frequencies of three 
different genotypes among the patients with Sight Threatening Diabetic Retinopathy 
are 26.9%- AA,53.8%-AG,19.3% -GG. Hence in both the groups the frequency of AG 
genotype is higher than the other two genotypes. However there is no statistically 
significant difference in the distribution of genotypes among the two groups.  
 
The frequency of A allele in our study population was  52 % and that of G allele was 
48% which similar to the allele frequency among the study population with diabetic 
retinopathy  in two studies done in South India done independently by Sankara 
Nethralaya 
97
and Aravind Eye Hospital
100
. 
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Among the Sight Threatening Diabetic Retinopathy group the frequency of  A allele 
was 53.9% and that of G allele was 46.1 %.The frequency distribution of A allele was 
50% and that of G allele was 50% among the Non Sight Threatening Group. No 
significant difference in the allele frequency was found between the two groups. 
 
Multivariate analysis between the patients with Sight Threatening Diabetic 
Retinopathy and Non Sight Threatening Diabetic retinopathy among the three 
genotypic variants of the ICAM-1 K469E polymorphism and various clinical 
covariates revealed that  factors like age ,sex, duration of diabetes ,co-existing co-
morbidities ,insulin requirement and fasting blood sugar did not influence the presence 
of Sight Threatening Diabetic retinopathy among the  three genotypes. However 
according to a population based study done in Sankara Nethralaya
97
 , the age of the 
patient among the patients with GG and AG genotypes and insulin requirement among 
those with any of the genotype influence the development of diabetic retinopathy. 
Though age of the patient and insulin requirement among diabetic patients along with 
genotypic variants of ICAM -1 Polymorphism influence the diabetic retinopathy 
development ,they have no effect on the development of sight threatening diabetic 
retinopathy. However due to small sample size in  the present study, further evidence 
is required to support this observation. 
 
The logistic regression analysis also revealed a negative association between the 
presence of  ocular manifestations of diabetes  other than retinopathy and AG 
genotype among patients with Sight Threatening Diabetic Retinopathy. Since various 
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other systemic and local factors  other than that due to diabetes might be involved in 
the development of these ocular manifestations, this observation in the present study 
has to be confirmed by further studies. 
 
The analysis reveals that a unit rise in the glycosylated haemoglobin increases the risk 
of developing sight threatening diabetic retinopathy by 1.96 times  among patients 
with GG genotype of ICAM-1K469E Polymorphism. The south Indian study done by 
Sankar Nethralaya also proves that elevation of glycosylated haemoglobin increases 
the risk of a diabetic patient  with any genotypic variant of ICAM-1 K469E 
polymorphism developing diabetic retinopathy by 1.32 to 1.48 folds
97
. However in 
their study they did not find the association between the severity of diabetic 
retinopathy among the genotypic variants of ICAM-1 K469E polymorphism and the 
glycosylated haemoglobin levels. The above observation indicates the fact that though 
elevated glycosylated haemoglobin levels among diabetic patients with any of the 
genotypic variants of ICAM-1 K469E polymorphism predisposes them to develop 
diabetic retinopathy, the presence of GG genotype among diabetic patients with 
elevated glycosylated haemoglobin level  increase the susceptibility of  their 
developing sight threatening diabetic retinopathy.  
 
Logistic Regression analysis performed with genotypic variants of ICAM-1K469E 
polymorphism as the dependent variable  with sequential addition of various clinical 
variables.Significant p value as not observed after adjusting for all the clinical 
covariates for any of the genotypic variants of  ICAM-1 K469E Polymorphism. 
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However odds ratio >1 though statistically not significant, is associated with GG 
phenotype compared to AA or AG phenotype which might indicate that G allele is the 
risk allele for developing Sight Threatening Diabetic Retinopathy which requires 
further study with large sample size to support this observation. 
 
Hence in this study no association was observed between any of the genotypes of 
ICAM-1K469E polymorphism and the development of sight threatening diabetic 
retinopathy after adjusting for various clinical confounding factors. However  the 
unadjusted  risk of developing  sight threatening diabetic retinopathy increased by 
1.96 times among diabetic patients with GG genotype of ICAM-1K469E 
polymorphism with elevated glycosylated haemoglobin levels in this study 
population. 
 
 Similar results were obtained in study done in Aravind Eye Hospital, where no 
association was found between ICAM-1  K469E Polymorphism and proliferative 
diabetic retinopathy
100
 .Hence it is evident that though  ICAM K469E polymorphism 
predisposes patient to develop diabetic retinopathy, it has no role in the development  
of sight threatening diabetic retinopathy.   
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Conclusion: 
Thus we conclude that 
 Age, sex, duration of diabetes, insulin requirement, Co-existing co-
morbidities, Fasting blood sugar levels and glycosylated haemoglobin 
levels  were not associated with severity of diabetic retinopathy in our 
study. 
 Ocular manifestations of diabetes other than retinopathy were 
significantly more among the patients with sight threatening diabetic 
retinopathy. 
 Frequency of AA genotype of  ICAM -1 K469E Polymorphism is  
25%,that of AG genotype is 54% and that of GG genotype is 21% in our 
study population. The frequency of A allele in our study population was  52 % 
and that of G allele was 48%. 
 There was  no significant difference in the frequency of alleles and genotype of 
ICAM -1 K469E Polymorphism among sight threatening and non sight 
threatening retinopathy. 
  The unadjusted  risk of developing  sight threatening diabetic retinopathy 
increased by 1.96 times among diabetic patients with GG genotype of ICAM-
1K469E polymorphism with elevated glycosylated haemoglobin levels in this 
study population. 
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 No association was observed between any of the genotypes of ICAM-1K469E 
polymorphism and the development of sight threatening diabetic retinopathy 
after the confounding effect of various clinical factors were removed. 
 
 Though  ICAM K469E polymorphism predisposes patient to develop 
diabetic retinopathy, it has no role in the development  of sight threatening 
diabetic retinopathy.   
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Need for the study: 
 
            The association of  ICAM-1 K469E polymorphism with diabetic retinopathy  
has been proved in caucasian and chinese population. However  two studies done in 
South India show conflicting results and these South Indian studies did not find the 
association of this polymorphism with the Sight threatening diabetic retinopathy. 
Hence, in this study we have found the association between the severity of diabetic 
retinopathy and ICAM-1 K469E polymorphism. If there is a significant association 
between the Sight Threatening Diabetic Retinopathy and  any of the genotypic variant 
of ICAM-1K469E polymorphism ,patients can be checked for the specific genotype of 
this  polymorphism at the time of diagnosis of type 2 diabetes and can be followed up 
frequently to prevent the sight threatening complications of diabetes.  
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Limitations of the study: 
 
 It is hospital based study so the study population tends to be more heterogenous 
compared to a population based study. 
 Small sample size involved in this study. 
 Due to money constraint and non uniformity of the clinical data available, not 
all clinical confounding factors of diabetic retinopathy could be included in this 
study. 
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The genotype phenotype correlation of ICAM1 K469E gene polymorphism and 
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7) GRADING OF DIABETIC RETINOPATHY BY ETDRS CLASSIFICATION: 
8) RESULT OF PCR RFLP FOR ICAM-1 K469E POLYMORPHISM: 
9) FASTING BLOOD SUGAR: 
10)   HBAIC LEVELS: 
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FBS HBA1c ICAM GENE POLYMORPHISM
1 63 M 8 NIL N 14.6 O MILD NPDR 218 9.88 WILD HOMOZYGOUS (A)
2 63 F 20 NIL N 17.3 O MILD NPDR 244 6.72 WILD HOMOZYGOUS (A)
3 65 M 5 NIL N 17.3 O MILD NPDR 131 12.57 HETEROZYGOUS (G/A)
4 55 M 15 SEPSIS N 17.3 O MILD NPDR 166 10.1 WILD HOMOZYGOUS (A)
5 66 F 12 SHT IMC 14.6 O MILD NPDR 142 8.02 HETEROZYGOUS (G/A)
6 60 M 6 SHT,CKD,ULCER, IMC 17.3 I MILD NPDR 167 10.94 MUTANT (G)
7 50 M 5 NIL ELC 17.3 I MILD NPDR 120 6.2 MUTANT (G)
8 45 F 5 NIL N 14.6 O MILD NPDR 138 10.89 HETEROZYGOUS (G/A)
9 75 M 5 SHT/CKD SI 17.3 O MILD NPDR 148 7.04 HETEROZYGOUS (G/A)
10 57 F 6 NIL N 12.2 O MILD NPDR 139 6.77 HETEROZYGOUS (G/A)
11 54 M 5 NIL N 17.3 O MILD NPDR 145 6.95 HETEROZYGOUS (G/A)
12 68 M 25 HT N 17.3 O MILD NPDR 130 6.5 HETEROZYGOUS (G/A)
13 51 M 5 NIL ELC 17.3 O MILD NPDR +CSME 110 9.69 WILD HOMOZYGOUS (A)
14 64 M 35 NIL HETRO.IRIS 14.6 O MILD NPDR 118 6.14 WILD HOMOZYGOUS (A)
15 67 M 10 NIL LE-PTOSIS 17.3 O MILD NPDR 223 9.29 HETEROZYGOUS (G/A)
16 69 M 18 SHT IMC 17.3 O MILD NPDR 178 7.94 HETEROZYGOUS (G/A)
17 65 F 15 SHT NAD 17.3 O MILD NPDR 156 10.43 HETEROZYGOUS (G/A)
18 60 F 20 SHT IMC 17.3 O MILD NPDR 247 10.01 WILD HOMOZYGOUS (A)
19 66 M 25 CVA+SHT IMC 17.3 I MILD NPDR 91 5.33 HETEROZYGOUS (G/A)
20 63 M 8 SHT+IHD IMC 14.6 O MILD NPDR 136 6.68 HETEROZYGOUS (G/A)
21 65 M 5 NIL PSPH 17.3 O MILD NPDR 73 4.7 WILD HOMOZYGOUS (A)
22 61 M 5 NIL IMC 17.3 I MILD NPDR 158 7.34 HETEROZYGOUS (G/A)
23 46 M 5 NIL IMC 17.3 I MILD NPDR 101 5.63 HETEROZYGOUS (G/A)
24 59 M 5 NIL IMC 17.3 O MILD NPDR 273 8.14 WILD HOMOZYGOUS (A)
25 49 M 5 NIL ELC 17.3 O MILD NPDR 246 11.76 MUTANT (G)
26 54 M 10 NIL N 12.2 O M  NPDR 91 5.33 HETEROZYGOUS (G/A)       
27 49 M 5 CVA N 14.6 O M.NPDR 213 8.9 HETEROZYGOUS (G/A)       
28 68 M 25 Pulmonary nodule N 17.3 O M.NPDR 137 6.71 HETEROZYGOUS (G/A)       
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29 59 M 17 SHT,RF PSPH 17.3 I+O M.NPDR 120 6.2 HETEROZYGOUS (G/A)       
30 57 M 8 SHT IMC 12.2 I+O M.NPDR 260 9.58 HETEROZYGOUS (G/A)       
31 59 M 5 RF NAD 17.3 I+O M.NPDR 223 9.29 HETEROZYGOUS (G/A)       
32 63 M 5 CAD ELC 12.2  O M.NPDR ,CSME 151 7.13 HETEROZYGOUS (G/A)       
33 52 F 5 NIL NAD 17.3 O M.NPDR 122 6.26 HETEROZYGOUS (G/A)       
34 55 M 6 CVA IMC 17.3 I+O M.NPDR 123 6.29 HETEROZYGOUS (G/A)       
35 50 M 5 DLD CIRRHOSIS NAD 17.3 O M.NPDR 114 6.02 HETEROZYGOUS (G/A)       
36 59 M 8 SHT IMC 17.3 O M.NPDR 91 7 HETEROZYGOUS (G/A)       
37 66 M 25 NAD NAD 17.3  I M.NPDR 161 6.8 HETEROZYGOUS (G/A)       
38 57 M 10 UPPER LID-PAPILLOMA ELC 17.3 O M.NPDR 121 6.23 HETEROZYGOUS (G/A)       
39 54 M 7 LVD,COPD,IHD IMC 17.3 O M.NPDR 117 5.81 HETEROZYGOUS (G/A)       
40 61 M 5 NAD NAD 17.3 O M.NPDR 240 9.8 MUTANT (G)               
41 48 M 6 NAD IMC 17.3 I M.NPDR 156 7.28 MUTANT (G)               
42 56 f 7 Nad IMC 17.3 O M.NPDR 130 13.4 MUTANT (G)               
43 72 M 38 SHT NAD 17.3 O M.NPDR,GR 2 HRT 120 7.82 MUTANT (G)               
44 80 M 15 HEMATOMA SCALP IMC 17.3 O M.NPDR 104 9.8 MUTANT (G)               
45 52 M 10 SHT,PN PSPH,IMC 17.3 O M.NPDR 347 13.01 MUTANT (G)               
46 52 M 5 NAD IMC 17.3 O M.NPDR 217 10.17 MUTANT (G)               
47 52 M 5 NAD IMC 17.3 O M.NPDR 175 7.85 MUTANT (G)               
48 52 M 8 NIL ELC 17.3 O M.NPDR 158 8.32 WILD HOMOZYGOUS (A)      
49 60 F 20 SHT,CM,CKD IMC ,CDC 17.3 I M.NPDR 150 7.1 WILD HOMOZYGOUS (A)      
50 63 M 15 SHT,CEREBELLAR INFARCT IMC 17.3 O M.NPDR 246 9.98 WILD HOMOZYGOUS (A)      
51 48 M 8 Nil NAD 17.3 O S NPDR 281 11.03 HETEROZYGOUS (G/A)       
52 58 M 10 NIL NAD 17.3 O S NPDR +CSME 131 6.53 HETEROZYGOUS (G/A)       
53 73 M 20 NIL IMC 10.4 O S.NPDR+CSME 170 7.7 HETEROZYGOUS (G/A)       
54 58 F 20 NIL PSPH 17.3 I S.NPDR+CSME 150 9.1 HETEROZYGOUS (G/A)       
55 53 F 8 SHT IMC 17.3 I+O S.NPDR+CSME 190 8.3 HETEROZYGOUS (G/A)       
56 54 F 10 NIL IMC 17.3 I+O S.NPDR+CSME 258 10.34 HETEROZYGOUS (G/A)       
57 62 M 15 NIL IMC 17.3 O S.NPDR 155 7.25 HETEROZYGOUS (G/A)       
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58 60 M 22 SHT ELC 17.3 O S.NPDR 128 9.6 HETEROZYGOUS (G/A)       
59 61 F 20 SHT ELC 17.3 I+O S.NPDR 112 5.96 HETEROZYGOUS (G/A)       
60 62 M 18 SHT NC 14.6 I S.NPDR 118 6.14 HETEROZYGOUS (G/A)       
61 61 M 17 POST CABG IMC 14.6 O S.NPDR+PRH+CSME 114 6.02 HETEROZYGOUS (G/A)       
62 69 F 10 DM,HT,RF ALT.EXOTROPIA 14.6 I S.NPDR +CSME+GR.3 HRT 134 6.32 HETEROZYGOUS (G/A)       
63 65 M 5 NAD NAD 17.3 O S.NPDR 144 9.3 HETEROZYGOUS (G/A) (G/A) 
64 58 F 15 NAD IMC 17.3 O S.NPDR 105 8.72 MUTANT (G)               
65 67 M 5 NSHT ELC 17.3 O S.NPDR 100 10.6 MUTANT (G)               
66 62 M 18 NAD IMC 17.3 I+O S.NPDR 313 11.69 MUTANT (G)               
67 60 M 14 NAD IMC 17.3 I S.NPDR 165 7.25 WILD HOMOZYGOUS (A)      
68 75 M 5 NAD IMC 17.3 O V.S.NPDR+PDR 118 5.84 WILD HOMOZYGOUS (A)      
69 57 M 6 SHT NAD 17.3 O S.NPDR 115 7.91 WILD HOMOZYGOUS (A)      
70 57 M 17 NAD IMC 17.3 O S.NPDR 239 6.7 WILD HOMOZYGOUS (A)      
71 50 F 10 NIL IMC 17.3 O S. NPDR. 233 9.59 WILD HOMOZYGOUS (A)      
72 62 F 20 Renal failure PSPH 17.3 O S.NPDR 119 6.17 WILD HOMOZYGOUS (A)      
73 65 F 15 NIL IMC 17.3 I+O S.NPDR 120 6.2 WILD HOMOZYGOUS (A)      
74 49 M 8 SHT IMC 17.3 I+O S.NPDR 259 10.37 WILD HOMOZYGOUS (A)      
75 63 F 15 SHT PSPH 17.3 I S.NPDR 168 7.64 WILD HOMOZYGOUS (A)      
76 62 M 13 NIL NAD 17.3 O PDR 321 12.23 HETEROZYGOUS (G/A)       
77 65 F 20 HEMIPLEGIA IMC,RD 17.3  I+O PDR 180 7.7 HETEROZYGOUS (G/A)       
78 62 M 15 SHT IMC 17.3 O PDR 179 7.97 HETEROZYGOUS (G/A)       
79 55 M 10 nil IMC 17.3 O PDR 290 11.3 HETEROZYGOUS (G/A)       
80 50 M 6 SHT +CKD PSPH 17.3 O+A PDR 388 10.83 HETEROZYGOUS (G/A)       
81 59 M 5 SHT PSPH 14.6 I+O HR PDR 149 7.07 HETEROZYGOUS (G/A)       
82 65 F 10 NIL RE-RAPD 17.3 O PDR+VH 190 6.54 HETEROZYGOUS (G/A)       
83 58 F 10 NAD ELC 17.3 I PDR+VH 139 6.77 HETEROZYGOUS (G/A)       
84 65 M 11 NAD PSPH,IMC 17.3 O PDR 130 6.7 HETEROZYGOUS (G/A)       
85 54 M 5 CORTICAL BLINDNEESSS ELC 17.3 O PDR 190 8.3 HETEROZYGOUS (G/A)       
86 59 M 5 SHT X 5Y RAPD WITH PCIOL 17.3 O POST PRP STABLE PDR 144 6.92 HETEROZYGOUS (G/A)       
S. NO AGE SEX
DIABETES 
DURATOION
CO-MORBIDITIES
EYE 
COMORBIDITIES
IOP
INSULIN
EQUIREMENT
GRADES OF 
DIABETIC  RETINOPATHY
FBS HBA1c ICAM GENE POLYMORPHISM
87 61 M 20 GR2PHARYNGEAL VARICES IMC 17.3 O PDR 248 10.04 HETEROZYGOUS (G/A)       
88 50 M 9 SHT X 5 Y IMC,N.PTERY 17.3 O PDR 264 10.52 HETEROZYGOUS (G/A)       
89 59 M 5 NIL R-RAPD 17.3 O PDR 141 11.78 HETEROZYGOUS (G/A)       
90 53 M 10 NAD NAD 17.3 O PDR 117 9.1 HETEROZYGOUS (G/A)       
91 58 M 10 NAD IMC,PXF,AST.HY 17.3 O PDR 97 5.51 MUTANT (G)               
92 66 F 13 NAD NAD 20.6 O PDR 342 11.38 MUTANT (G)               
93 65 M 17 SHT X 2Y,LUMBAR SPONDYLOSISNAD 17.3 O PDR 180 10.86 MUTANT (G)               
94 52 M 7 SHT-7Y,CKD,HD PSL,PSPH 17.3 O+AVS INJ PDR 83 5.09 MUTANT (G)               
95 64 M 15 SHT,GERD NAD 17.3 I+O PDR 110 7.8 MUTANT (G)               
96 62 M 15 SHT-7,GLUTEAL ABSCESS NAD 17.3 O PDR 168 9.2 MUTANT (G)               
97 52 M 5 SHT-2 IMC 17.3 I PDR 156 7.28 WILD HOMOZYGOUS (A)      
98 54 M 5 SHT,CAD IMC 17.3 I+O PDR 121 6.23 WILD HOMOZYGOUS (A)      
99 53 M 7 PVD IMC 17.3 O PDR 111 5.93 WILD HOMOZYGOUS (A)      
100 51 M 5 Gangrene leg ELC 17.3 O PDR 156 7.28 WILD HOMOZYGOUS (A)      
- Oral hypo glycemics
I - Insulin
N - Normal 
IMC - Immature Cataract
PXF - Pseudoexfoliation
SHT - systemic  Hypertension
CAD - Coronary Artery Disease
PVD - Peripheral Vascular Disease
NPDR - Non Proliferative Diabetic Retinopathy
PDR -  Proliferative Diabetic Retinopathy
RAPD - Relative Afferant Pupillary Defect
PCIOL - Posterior Capsular  Intraocularlens 
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